WO2016019176A1 - Methods and compositions for diagnosing, prognosing, and confirming preeclampsia - Google Patents

Methods and compositions for diagnosing, prognosing, and confirming preeclampsia Download PDF

Info

Publication number
WO2016019176A1
WO2016019176A1 PCT/US2015/042976 US2015042976W WO2016019176A1 WO 2016019176 A1 WO2016019176 A1 WO 2016019176A1 US 2015042976 W US2015042976 W US 2015042976W WO 2016019176 A1 WO2016019176 A1 WO 2016019176A1
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
preeclampsia
levels
subject
sflt
Prior art date
Application number
PCT/US2015/042976
Other languages
English (en)
French (fr)
Inventor
Matthew Cooper
Lyndal HESTERBERG
Eric KUNKEL
Evangelos Hytopoulos
Kimberly SCHWARTZ
Original Assignee
Matthew Cooper
Hesterberg Lyndal
Kunkel Eric
Evangelos Hytopoulos
Schwartz Kimberly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthew Cooper, Hesterberg Lyndal, Kunkel Eric, Evangelos Hytopoulos, Schwartz Kimberly filed Critical Matthew Cooper
Priority to CA2956646A priority Critical patent/CA2956646A1/en
Priority to CN201580052632.5A priority patent/CN107155350A/zh
Priority to EP15826348.3A priority patent/EP3175239A1/en
Publication of WO2016019176A1 publication Critical patent/WO2016019176A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Definitions

  • This disclosure pertains to providing a preeclampsia diagnosis and prognosis.
  • PE Preeclampsia
  • the incidence of the disorder is around 5-8% of all pregnancies in the U.S. and worldwide, and the disorder is responsible for 18% of all maternal deaths in the U.S.
  • the causes and pathogenesis of preeclampsia remain uncertain, and current laboratory signs and clinical symptoms of PE occur late in the disease process, sometimes making the determination of PE and clinical management decisions difficult.
  • Earlier and more reliable diagnosis, prognosis, confirmation and monitoring of the disease will lead to more timely and personalized preeclampsia treatments and as such, will significantly advance the
  • the disclosure provides a method for confirming preeclampsia in any subject, preferably a pregnant subject, comprising: evaluating a plurality of biomarkers in a sample derived from the subject to calculate an index or to confirm if the subject has preeclampsia wherein the confirmation has a sensitivity of greater than 90%, a specificity of greater than 90%, or greater than 0.9 area under the receiver operating characteristic curve (ROC and/or AUC).
  • ROC and/or AUC receiver operating characteristic curve
  • the disclosure provides a test for confirming preeclampsia in a subject, preferably a pregnant subject, wherein the test is able to discern subjects not having PE but having one or more symptoms associated with PE from subjects having by PE, with a ROC value of at least 0.80, 0.85, 0.90, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99, 0.995 or more.
  • the one or more symptoms associated with PE can be diabetes (e.g. gestational, type I or type II), higher than normal glucose level, hypertension (e.g.
  • the disclosure provides a test for confirming preeclampsia in a subject, preferably a pregnant subject, wherein the test is able to discern subjects not having PE but having one or more symptoms associated with PE from subjects having PE, with a sensitivity, specificity and/or negative predictive value (NPV) of at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%), 99.5%) or more.
  • the one or more symptoms associated with PE can be diabetes (e.g. gestational, type I or type II), higher than normal glucose level, hypertension (e.g. chronic or non-chronic), excessive or sudden weight gain, higher than normal weight, obesity, higher than normal body mass index (BMI), abnormal weight gain, abnormal blood pressure, water retention, hereditary factors, abnormal proteinurea, headache, edema, abnormal
  • the disclosure provides a method for confirming preeclampsia in a subject, preferably a pregnant subject, comprising performing a test on a sample derived from the subject, wherein the test comprises measuring the levels of a plurality of markers and using the levels to confirm PE with a sensitivity, specificity and/or negative predictive value (NPV) of at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or more, or a ROC value of at least 0.80, 0.85, 0.90, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99, 0.995 or more.
  • the one or more symptoms associated with PE can be diabetes (e.g.
  • gestational type I or type II
  • hypertension e.g. chronic or non-chronic
  • excessive or sudden weight gain higher than normal weight
  • obesity higher than normal body mass index (BMI)
  • abnormal weight gain abnormal blood pressure, water retention, hereditary factors, abnormal proteinurea, headache, edema, abnormal protein/creatinine ratio, abnormal platelet count, stress, nulliparity, abnormal Papanicolaou test results (Pap smear), prior preeclampsia episodes (i.e. personal history of PE), familial history of PE, PE in prior pregnancies, renal disease, thrombophilia, or any combination thereof.
  • the disclosure further provides a method for confirming if a subject, preferably a pregnant subject, does not have preeclampsia, the method comprising: evaluating a sample derived from the subject to determine levels of a plurality of biomarkers in the sample, using the levels of the plurality of biomarkers to calculate an index representative of a likelihood that the subject does not have preeclampsia; and based upon the index, confirming if the subject does not have preeclampsia.
  • a method for confirming if a subject, preferably a pregnant subject, does have preeclampsia comprising: (a) evaluating a sample derived from the subject to determine levels of a plurality of biomarkers in the sample, (b) using the levels of the plurality of biomarkers to calculate an index representative of a likelihood that the subject does have preeclampsia; and (c) based upon the index, confirming if the subject does have preeclampsia.
  • the disclosure further provides method for confirming if a subject, preferably a pregnant subject, does not have preeclampsia, the method comprising: (a) evaluating a sample derived from the subject to determine a level of a biomarker in the sample; and (b) using the level of the biomarker to calculate an index representative of the likelihood that the subject does not have preeclampsia, wherein the biomarker is not ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M),
  • FT ferritin
  • CTSB cathepsin B
  • CSC cathepsin C
  • HP haptoglobin
  • A2M alpha-2-macroglobulin
  • apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-l (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM) or heme.
  • ApoE apolipoprotein E
  • Apo-C3 apolipoprotein C-III
  • ApoAl apolipoprotein A-l
  • RBP4 retinol binding protein 4
  • HB hemoglobin
  • FGA fibrinogen alpha
  • FGA fibrinogen alpha
  • EGFLAM pikachurin
  • the disclosure provides a method for confirming if a subject, preferably a pregnant subject, does have preeclampsia, the method comprising: (a) evaluating a sample derived from the subject to determine a level of a biomarker in the sample; and (b) using the level of the biomarker to calculate an index representative of the likelihood that the subject does have preeclampsia, wherein the biomarker is not ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotem E (ApoE), apolipoprotem C-III (Apo-C3), apolipoprotem A-1 (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM) or heme.
  • FT ferritin
  • the disclosure further provides a method for confirming if a subject, preferably a pregnant subject, having at least one symptom associated with PE has PE, the method comprising: (a) evaluating a sample derived from the subject to determine a level of one or more biomarkers in the sample; and (b) calculating an index representative of a likelihood that the woman does have PE using the levels of the one or more biomarkers to calculate an index, wherein the one or more biomarkers are not ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotem E
  • FT ferritin
  • CTSB cathepsin B
  • CSC cathepsin C
  • HP haptoglobin
  • A2M alpha-2-macroglobulin
  • ApoE apolipoprotem C-III
  • Apo-C3 apolipoprotem A-1
  • RBP4 retinol binding protein 4
  • HB hemoglobin
  • FGA fibrinogen alpha
  • FGA pikachurin
  • EGFLAM pikachurin
  • the disclosure further provides a method for confirming if a subject, preferably a pregnant subject, not having at least one symptom associated with PE does not have PE, the method comprising: (a) evaluating a sample derived from the subject to determine a level of one or more biomarkers in the sample; and (b) calculating an index representative of a likelihood that the subject does not have PE using the levels of the one or more biomarkers to calculate an index, wherein the one or more biomarkers are not ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M),
  • apolipoprotem E (ApoE), apolipoprotem C-III (Apo-C3), apolipoprotem A-1 (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM) or heme.
  • the disclosure further provides a method for diagnosing or confirming a presence of preeclampsia in a subject, preferably a pregnant subject, the method comprising: (a) performing a plurality of different assays that determine a level of fibronectin in a sample derived from the subject; and (b) evaluating the sample and using the levels from the plurality of different assays to diagnose or confirm the existence of preeclampsia and calculate an index.
  • the disclosure further provides a method for confirming that a subject, preferably a pregnant subject, does not have preeclampsia, the method comprising: performing a plurality of different assays that determine a level of fibronectin in a sample derived from the subject; and evaluating the sample and using the levels from the plurality of assays to confirm the subject does not have preeclampsia and calculate an index.
  • the disclosure further provides a method for diagnosing or confirming a presence of preeclampsia in a subject, preferably a pregnant subject, the method comprising: (a) performing at least one assay which utilizes an antibody which binds fibronectin or an antibody that selectively binds a same antigen of fibronectin as the antibody, wherein the binding of the antibody determines a level of fibronectin in a sample derived from the subject; and (b) evaluating the sample and using the level of fibronectin from the at least one assay to diagnose or confirm the existence of preeclampsia and calculate an index.
  • the disclosure further provides a method for diagnosing or confirming a presence of preeclampsia in a subject, preferably a pregnant subject, the method comprising: (a) measuring a level of a ratio of sFlt-1 and P1GF (PLGF) and a level a plurality of different biomarkers in a sample derived from the subject, wherein none of the different biomarkers is ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2- macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3),
  • apolipoprotein A-l (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM) or heme; and (b) evaluating the sample and using the level from step (a) to determine an index to diagnose or confirm the presence of preeclampsia and calculate an index.
  • AmpoAl apolipoprotein A-l
  • RBP4 retinol binding protein 4
  • HB hemoglobin
  • FGA fibrinogen alpha
  • EGFLAM pikachurin
  • the disclosure further provides a method for diagnosing, monitoring, characterizing or confirming preeclampsia by evaluating a sample derived from a subject, preferably a pregnant subject, by using the levels of at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 markers (e.g., biomarkers) selected from Figures 5A-5F (or Table 2) to calculate an index value, wherein the index value is used to determine a diagnosis, relative level, or characterization
  • markers e.g., biomarkers
  • the disclosure further provides a method for confirming a subject, preferably a pregnant subject, does not have preeclampsia consisting of: measuring a level of a ratio of sFlt-1 and P1GF and a level of a plurality of different biomarkers in a sample derived from the subject, wherein none of the different biomarkers is ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-l (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM) or heme; and evaluating the sample and using the level from step (a) to determine an index to confirm the absence of pre
  • the disclosure further provides a method for distinguishing a subject having preeclampsia from a subject not having preeclampsia but having symptoms associated with preeclampsia.
  • symptoms associated with preeclampsia include, e.g., chronic hypertension, gestational hypertension, autoimmune disorders and/or gestational diabetes.
  • the methods and tests herein have a specificity, sensitivity and/or negative predictive value (NPV) of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%o, 99%), or 99.5%.
  • NPV negative predictive value
  • the methods and tests herein preferably distinguish between a subject having preeclampsia from a subject not having preeclampsia but having symptoms associated with preeclampsia with a ROC value or area under the curve value of at least 0.8, 0.85, 0.9, or 0.95.
  • the methods herein comprise measuring the level of a plurality of different biomarkers (e.g., such as those selected from the list in Figures 5A-5F (or Table 2)) in a sample derived from a subject, generating an index using the levels of the different index, and using the index as a means to confirm the presence of preeclampsia, absence of preeclampsia, and/or severity of preeclampsia.
  • the disclosure further provides a method for confirming the presence, absence or severity of preeclampsia in a subject, preferably a pregnant subject, the method comprising: utilizing a monoclonal antibody that selectively binds fibronectin to determine the levels of fibronectin in a sample derived from the subject, generating a report indicating the presence, absence or severity of preeclampsia based on the levels and containing an index; evaluating the sample; and based upon the index, suggesting a treatment for preeclampsia, , wherein the treatment involves aspirin, preterm labor, treatment with anti-hypertensive or anti- preeclampsia drugs, or bedrest.
  • the disclosure further provides a method for confirming the presence, absence or severity of preeclampsia in a sample derived from a subject, preferably a pregnant subject, the method comprising: utilizing an antibody directed to the antigen of the fibronectin antibody in at least one fibronectin ELISA kit to analyze and evaluate a sample derived from the subject.
  • the disclosure further provides a method for confirming the presence, absence or severity of preeclampsia in a subject, preferably a pregnant subject, the method comprising: performing at least one assay which utilizes an antibody that selectively binds fibronectin, a portion of fibronection, a part of fibronectin, or a fragment of fibronectin, wherein the binding of the antibody determines the level of fibronectin in a sample derived from the subject; evaluating the sample; and using the level of fibronectin from the at least one assay to confirm the presence, absence, or severity of preeclampsia and calculate an index.
  • the disclosure further provides a test for confirming an absence of preeclampsia in a subject, preferably a female subject, wherein the test measures one or more biomarkers from a sample derived from the subject, wherein the test has an overall ROC value of at least 0.8. In some examples, the test measures one or more biomarkers from a sample derived from a subject, wherein the test has an overall ROC value of at least 0.7, 0.8, 0.85, 0.9, 0.95, 0.96, 0.97, 0.98, 0.99 or more.
  • the test measures one or more biomarkers from a sample derived from a subject and has an overall ROC value of at 0.81, 0.82, 0.83, 0.84, 0.85, 0.86, 0.87, 0.88, 0.89, 0.9, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99, 0.995 or more.
  • the disclosure further provides a kit for confirming, diagnosing, prognosing, monitoring or characterizing preeclampsia in a subject, preferably a pregnant subject, said kit comprising at least two reagents that are specific for determining level of fibronectin in a sample derived from the subject.
  • the disclosure further provides a business method comprising the step of
  • determining presence, absence, forecast, severity or character of preeclampsia in a subject preferably a pregnant subject
  • said method comprising the steps of: (a) evaluating levels of sFLT-1, P1GF and a plurality of different biomarkers in a sample derived from the subject, wherein the none of the different biomarkers is ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-l (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM) or heme, (b) determining a biomarker index value, said index comprising sFLT-l/PlGF and the
  • the disclosure further provides a system for confirming , diagnosing, prognosing, monitoring or characterizing preeclampsia in a subject, preferably a pregnant subject, comprising: (a) an input module for receiving as an input levels of sFLT-1, P1GF and a plurality of different biomarkers, (b) a processor optionally configured to perform a log transformation of said levels to obtain log transformed levels, normalize each of said log transformed levels to normalized levels, adjust each of said normalized levels to a weighted normalized level, total each of the adjusted levels, average each of the adjusted levels; and provide a preeclampsia index based on said score wherein the index score comprises sFLT- 1/PlGF and an addition of the plurality of different biomarkers.
  • the log transformation is a natural, common, binary, rational or irrational log transformation.
  • the log transformation is log 2 , logio or log e transformation.
  • the log transformation is logb, where the logarithmic base is any real number (including natural numbers, rational number or irrational number).
  • This disclosure further provides a method for confirming that a subject, preferably a pregnant subject, does not have preeclampsia comprising: evaluating a plurality of biomarkers in a sample derived from the subject to confirm the subject does not have preeclampsia wherein the confirmation has a specificity of greater than 90% or has an 0.9 AUC and is used to calculate an index.
  • a method for determining the severity of preeclampsia or for confirming the presence or absence of preeclampsia in a female subject comprising:
  • a method for diagnosing, pronging, monitoring, characterizing, determining the severity of preeclampsia or confirming the presence or absence of preeclampsia in a female subject the presence or absence of preeclampsia in a female subject comprising:
  • a method for diagnosing, pronging, monitoring, characterizing, determining the severity of preeclampsia or confirming the presence or absence of preeclampsia in a female subject comprising:
  • FN fibronectin
  • the two or more biomarkers are selected from the group consisting of sFLT-1, P1GF, ADAM- 12, HPX and PAPP-A.
  • biomarkers are sFLT-1 , P1GF, PAPP-A and ADAM- 12.
  • the one or more biomarkers are sFLT-1 , P 1 GF, PAPP-A and HPX.
  • biomarkers are P1GF, PAPP- A and ADAM- 12.
  • biomarkers are sFLT-1 , P1GF and ADAM- 12.
  • a method for confirming preeclampsia or the absence of preeclampsia in a female subject comprising:
  • FN fibronectin
  • biomarkers are selected from the group consisting of sFLT-1, P1GF, ADAM- 12, HPX and PAPP-A.
  • biomarkers are sFLT-1, P1GF, PAPP-A and ADAM- 12.
  • biomarkers are sFLT-1, P 1 GF, PAPP-A and HPX.
  • biomarkers are sFLT-1, P1GF and AD AM-12.
  • a method for diagnosing, pronging, characterizing, monitoring, determining the severity of preeclampsia or confirming preeclampsia or the absence of preeclampsia in a female subject comprising:
  • biomarkers are selected from the group consisting of fibronectin (FN), ADAM- 12, HPX and PAPP-A.
  • biomarkers are fibronectin (FN).
  • a method for diagnosing, pronging, characterizing, monitoring, determining the severity of preeclampsia or confirming preeclampsia or the absence of preeclampsia in a female subject comprising: a) measuring levels of least one fibronectin (FN) fragment in two different assays, wherein the assays determine the level of FN in a sample derived from the pregnant female; and
  • each of the different assays utilizes a different monoclonal antibody.
  • biomarkers are selected from the group consisting of sFLT-1, P1GF, ADAM- 12, HPX and PAPP-A.
  • the one or more biomarkers are sFLT-1 , P IGF and PAPP-A.
  • the level of each of the one or more biomarker levels is input into a specific variable of the one or more variables, wherein the corresponding weight factor is unique for each specific variable, wherein at least one of the corresponding weight factor is different from one.
  • biomarkers are selected from the group consisting of sFLT-1, PIGF, fibronectin (FN), ADAM- 12, HPX and PAPP-A.
  • biomarkers exclude ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2- macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-l (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM), free human chorionic gonadotropin (free beta hCG) and heme.
  • FT ferritin
  • CTSB cathepsin B
  • CSC cathepsin C
  • HP haptoglobin
  • A2M alpha-2- macroglobulin
  • A2M apolipoprotein E
  • ApoE apolipoprotein C-III
  • Apo-C3 apolipoprotein A-l
  • comparing is comparing of the one or more biomarkers to a single pregnant female or to a group of pregnant females experience PE and a group of pregnant females not experiencing PE.
  • comparing comprises comparing of the one or more biomarkers to a respective recombinant protein index value.
  • biomarkers comprise one or more proteins or protein fragments.
  • biomarkers comprise polynucleotides.
  • the immunological assay is selected from the group consisting of ELISA, sandwich ELISA, competitive ELISA and IgM antibody capture ELISA.
  • kits for diagnosing, prognosing, monitoring, characterizing, determining the severity of preeclampsia or for confirming the presence or absence of preeclampsia in a pregnant female comprising: at least two different reagents that are specific for determining a level of fibronectin (FN) in a sample from the pregnant female.
  • FN fibronectin
  • kit of claim 65 further comprising two or more reagents measuring levels of two or more biomarkers in a sample derived from the female subject.
  • kits of claim 66, wherein the two or more biomarkers are sFLT-1, P1GF and PAPP-A.
  • the two or more biomarkers are sFLT-1, P1GF, PAPP-A and ADAM-12.
  • kits of claim 66, wherein the two or more biomarkers are sFLT-1, P1GF, PAPP-A and HPX.
  • kits of claim 66, wherein the two or more biomarkers are PI GF, PAPP-A and ADAM-12.
  • kits of claim 66, wherein the two or more biomarkers are sFLT-1 and P1GF.
  • kits of claim 66 wherein the two or more biomarkers are P1GF and PAPP- A.
  • kits of claim 66, wherein the two or more biomarkers are sFLT-1, P1GF and ADAM-12.
  • kits of claim 66, wherein the two or more biomarkers are sFLT-1 and ADAM-12.
  • kit of claim 65 or 66 wherein the kit does not include a reagent measure the levels of biomarkers selected from the group consisting of ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-l
  • EpoAl retinol binding protein 4
  • RBP4 retinol binding protein 4
  • HB hemoglobin
  • FGA fibrinogen alpha
  • FGA fibrinogen alpha
  • EGFLAM pikachurin
  • kits for confirming the presence or absence of preeclampsia in a pregnant female the kit comprises
  • kit of claim 76 further comprising one or more reagents measuring levels of one or more biomarkers in a sample derived from the female subject.
  • kits of claim 77 wherein the one or more biomarkers are sFLT-1, P1GF and fibronecting (FN).
  • kits of claim 77, wherein the one or more biomarkers are P1GF and fibronecting (FN). 80.
  • FGA pikachurin
  • EGFLAM pikachurin
  • free beta hPC free beta hPC and heme.
  • kits for diagnosing, prognosing, monitoring, characterizing, determining the severity of preeclampsia, or for confirming the presence or absence of preeclampsia in a pregnant female comprises:
  • a third reagent specific for determining a level of a biomarker that is different from the biomarker determined by the first and second reagent a third reagent specific for determining a level of a biomarker that is different from the biomarker determined by the first and second reagent.
  • the kit of claim 81 wherein the first reagent determines the levels of sFLT- 1 , the third reagent determines the levels of P IGF, and the kit further comprises a fourth reagent determining the level of a biomarker different from sFLT-1, P1GF and FN.
  • FT cathepsin B
  • CCTSC cathepsin C
  • haptoglobin HP
  • alpha-2- macroglobulin A2M
  • apolipoprotein E ApoE
  • apolipoprotein C-III Apo-C3
  • apolipoprotein A-l ApoAl
  • RBP4 retinol binding protein 4
  • HB hemoglobin
  • FGA fibrinogen alpha
  • FGA fibrinogen alpha
  • EGFLAM free beta hPC and heme.
  • test for confirming the presence or the absence of preeclampsia in a pregnant female wherein the test measures one or more biomarkers from a sample derived from the pregnant female and has an overall ROC value of at least 0.8 or more.
  • a computer readable medium having an executable logic for diagnosing, pronging, characterizing, monitoring, determining the severity of preeclampsia or confirming the presence or absence of preeclampsia in a female subject comprising:
  • a computer readable medium having an executable logic for confirming the presence or absence of preeclampsia in a female subject comprising:
  • a computer readable medium having an executable logic for confirming the presence or absence of preeclampsia in a female subject comprising:
  • (k) algorithm comprising a ratio between two of the one or more adjusted biomarker levels, wherein the algorithm is a real function that results in an index value
  • the corresponding weight factor is unique for each specific variable or unique for each specific ratio of two variables.
  • the computer readable medium of claim 90 further comprising an algorithm for averaging each of the one or more adjusted biomarker levels.
  • the computer readable medium of claim 90 wherein the computer readable medium further comprises an algorithm for performing a logarithmic transformation of the levels to obtain log transformed levels; algorithm for normalizing each of the log transformed levels to normalized levels; algorithm for adjusting each of the normalized levels to a weighted normalized level.
  • a computer readable medium having an executable logic for diagnosing, prognosing, monitoring, characterizing, determining the severity of preeclampsia or for confirming the presence or absence of preeclampsia in a pregnant female comprising:
  • the corresponding weight factor is unique for each specific variable, wherein at least one of the corresponding weight factor is different from one;
  • the computer readable medium of claim 98 wherein the subjects are at least 150 subjects or more.
  • a method for confirming a presence or absence of preeclampsia in a female subject comprising:
  • biomarkers comprise measuring levels of three or more biomarkers.
  • biomarkers comprise measuring levels of four or more biomarkers.
  • biomarkers comprise measuring levels of five or more biomarkers.
  • a method for confirming a presence or absence of preeclampsia in a female subject comprising:
  • a method for confirming a presence or absence of preeclampsia in a female subject comprising:
  • FN fibronectin
  • biomarkers a) measuring levels of fibronectin (FN) and two or more biomarkers in a sample derived from the female subject, wherein at least two of the two or more biomarkers are different from fibronectin, b) calculating an index based on the levels of FN and the two or more biomarkers;
  • the two or more biomarkers are selected from the group consisting of sFLT-1, PIGF, ADAM-12, HPX and PAPP-A.
  • biomarkers are sFLT-1, PIGF and PAPP- A.
  • biomarkers are sFLT-1, PIGF, PAPP-A and ADAM-12.
  • biomarkers are sFLT- 1 , P 1 GF, PAPP-A and HPX.
  • biomarkers are PIGF, PAPP-A and
  • biomarkers are sFLT-1 and PIGF.
  • biomarkers are PIGF and PAPP-A.
  • biomarkers are sFLT-1, PIGF and
  • biomarkers are sFLT-1 and ADAM-12.
  • biomarkers are PIGF, ADAM-12, sFLTl,
  • a method for confirming a presence or absence of preeclampsia in a female subject comprising:
  • FN fibronectin
  • biomarkers are selected from the group consisting of sFLT-1, PIGF, ADAM- 12, HPX and PAPP-A.
  • biomarkers are sFLT-1, PIGF and PAPP-A.
  • biomarkers are sFLT-1, PIGF, PAPP-A and ADAM-12.
  • biomarkers are sFLT-1, PIGF, PAPP-A and HPX.
  • biomarkers are PIGF, PAPP-A and ADAM-12.
  • biomarkers are sFLT-1 and PIGF.
  • biomarkers are PIGF and PAPP-A.
  • biomarkers are sFLT-1, PIGF and ADAM-12.
  • biomarkers are sFLT-1 and ADAM-12.
  • biomarkers are PIGF, FN, ADAM-12, sFLTl, PAPP-A2, and HPX.
  • the method of claim 20, 22, 23, 24, 25, 26, 27, 28 or 29 further comprising calculating an index based on levels of (1) bound monoclonal antibodies and (2) the two or more biomarkers.
  • the method of claims 31 or 32 further comprising comparing the index to a threshold value, wherein the index is indicative of the presence or absence of preeclampsia in the female subject.
  • a method for confirming a presence or absence of preeclampsia in a female subject comprising:
  • biomarkers are selected from the group consisting of fibronectin (FN), ADAM- 12, HPX and PAPP-A.
  • biomarkers are PAPP-A.
  • biomarkers are fibronectin (FN).
  • biomarkers are fibronectin (FN) and PAPP-A.
  • biomarkers are fibronectin (FN) and ADAM-12.
  • biomarkers are fibronectin (FN)
  • ADAM-12 and PAPP-A are ADAM-12 and PAPP-A.
  • biomarkers are fibronectin (FN), HPX and PAPP-A.
  • biomarkers are FN, ADAM-12, PAPP-A2, and HPX.
  • a method for confirming a presence or absence of preeclampsia in a female subject comprising:
  • the calculating comprises multiplying each of the measured levels of sFLT and PIGF by a unique weight factor, and applying one or more binary functions to weighted measured levels of sFLT and PIGF.
  • a method for diagnosing, prognosing, characterizing, monitoring, determining a severity of, confirming a presence of, or confirming an absence of preeclampsia in a female subject comprising:
  • the assays determine the level of FN in a sample derived from the female subject
  • each of the two different assays utilizes a different monoclonal antibody.
  • biomarkers are selected from the group consisting of sFLT-1, PIGF, ADAM-12, HPX and PAPP-A.
  • biomarkers are sFLT-1 or PIGF.
  • biomarkers are sFLT-1, PIGF or PAPP-
  • biomarkers are sFLT-1, PIGF or
  • biomarkers are PIGF, ADAM-12, sFLTl, PAPP-A2, and HPX. 55. The method of claims 49, 50, 51, 52, 53, or 54, further comprising calculating an index based on the levels of (1) bound monoclonal antibodies and (2) the one or more biomarkers.
  • the index is calculated by a real function algorithm for totaling measured levels of biomarker levels, wherein the algorithm comprises multiplying one or more variables by one or more corresponding weight factors,
  • a corresponding weight factor is unique for each specific variable, wherein at least one of the one or more corresponding weight factors is different from one.
  • the one or more biomarkers are selected from the group consisting of sFLT-1, P1GF, fibronectin (FN), ADAM- 12, HPX and PAPP-A.
  • biomarkers exclude ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-l (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM), free human chorionic gonadotropin (free beta hCG) and heme.
  • ferritin F
  • CTSB cathepsin B
  • CSC cathepsin C
  • HP haptoglobin
  • A2M alpha-2-macroglobulin
  • A2M apolipoprotein E
  • ApoE apolipoprotein C-III
  • Apo-C3 apolipoprotein A-l
  • comparing comprises comparing the biomarkers to (1) that of a single pregnant female or a group of pregnant females having preeclampsia and (2) that of a group of pregnant females not having preeclampsia.
  • the method of claim 70 wherein the comparing comprises comparing the biomarkers to a respective recombinant protein index value.
  • biomarkers comprise one or more proteins or protein fragments.
  • biomarkers comprise polynucleotides.
  • the method of claim 1, 5, 7, 19, 34 or 47, wherein the measuring comprises utilizing an immunological assay, mass spectrometry, chromatography, nephelometry, radial immunodiffusion or single radial immunodiffusion assay.
  • the measuring comprises measuring by an immunological assay.
  • the method of claim 76 wherein the immunological assay is selected from the group consisting of ELISA, sandwich ELISA, competitive ELISA and IgM antibody capture ELISA.
  • the kit comprising: at least two different reagents that are specific for determining a level of fibronectin (FN) in a sample derived from the female subject.
  • FN fibronectin
  • the kit of claim 78 further comprising two or more reagents for measuring levels of two or more biomarkers in the sample derived from the female subject.
  • the kit of claim 79, wherein the biomarkers are sFLT-1, P1GF and PAPP-A.
  • the kit of claim 79, wherein the biomarkers are sFLT-1, P1GF, PAPP-A and ADAM- 12.
  • the kit of claim 79, wherein the biomarkers are sFLT-1, PIGF, PAPP-A and HPX.
  • kits of claim 79, wherein the biomarkers are P 1 GF, PAPP-A and AD AM- 12.
  • kits of claim 79, wherein the biomarkers are sFLT-1 and PIGF.
  • kits of claim 79, wherein the biomarkers are PIGF and PAPP-A.
  • kits of claim 79, wherein the biomarkers are sFLT-1, PIGF and ADAM- 12.
  • kits of claim 79, wherein the biomarkers are sFLT-1 and ADAM-12.
  • kits of claim 79, wherein the biomarkers are PIGF, FN, ADAM-12, sFLTl,
  • biomarkers selected from the group consisting of ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-l (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM), free beta hPC and heme.
  • FT ferritin
  • CTSB cathepsin B
  • CSC cathepsin C
  • HP haptoglobin
  • A2M alpha-2-macroglobulin
  • A2M apolipoprotein E
  • ApoE apolipoprotein C-III
  • Apo-C3 apolipoprotein A-l
  • RBP4
  • kits for confirming the presence or absence of preeclampsia in a female subject comprising:
  • kit of claim 90 further comprising one or more reagents for measuring levels of one or more biomarkers in a sample derived from the female subject.
  • kits of claim 91 wherein the biomarkers are sFLT-1, PIGF and fibronectin (FN).
  • kits of claim 91 wherein the biomarkers are PIGF and fibronectin (FN).
  • biomarkers selected from the group consisting of ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2- macroglobulin (A2M), apolipoprotein E (ApoE), apo lipoprotein C-III (Apo- C3), apolipoprotein A-l (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM), free beta hPC and heme.
  • the kit comprising:
  • a third reagent specific for determining a level of a biomarker that is different from biomarker determined by the first and second reagent a third reagent specific for determining a level of a biomarker that is different from biomarker determined by the first and second reagent.
  • the kit of claim 95 wherein the first reagent is specific for determining the level of sFLT-1, the third reagent is specific for determining the level of P1GF, and the kit further comprises a fourth reagent specific for determining a level of a biomarker different from sFLT-1, P1GF and FN.
  • kits of claim 96, wherein the fourth reagent is specific for determining the levels of PAPP-A, HPX or ADAM 12.
  • FT ferritin
  • CTSB cathepsin B
  • CTSC cathepsin C
  • HP haptoglobin
  • A2M alpha-2-macroglobulin
  • A2M apolipoprotein E
  • ApoE apolipo
  • a receiver operating characteristic (ROC) value associated with the biomarkers is at least 0.8.
  • a test for confirming a presence or absence of preeclampsia in a subject wherein the test measures one or more biomarkers from a sample derived from the subject, wherein a receiver operating characteristic (ROC) value associated with the biomarkers is greater than a ROC value associated with sFLT/PlGF.
  • ROC receiver operating characteristic
  • test of claim 104 wherein the test comprises measuring a ratio of
  • a system for diagnosing, prognosing, characterizing, monitoring, determining a severity of, confirming a presence of, or confirming an absence of preeclampsia in a female subject comprising:
  • an output module for outputting the index value, wherein the index value indicates diagnosis, prognosis, characterization, a monitored aspect, determination of the severity, confirmation of the presence, or confirmation of the absence, of preeclampsia in the female subject.
  • a system for confirming a presence or absence of preeclampsia in a female subject comprising:
  • an input module for receiving as an input levels of one or more biomarkers;
  • a processor configured to:
  • biomarker levels wherein the second algorithm is a real function that results in an index value
  • a system for confirming a presence or absence of preeclampsia in a female subject comprising:
  • a system for diagnosing, prognosing, monitoring, characterizing, determining a severity of, confirming a presence of, or confirming an absence of preeclampsia in a female subject comprising:
  • the training set is based on a model.
  • the training set is based on real values obtained from subjects.
  • a test for confirming preeclampsia in a subject wherein the test is able to discern subjects that do not have preeclampsia but have one or more symptoms associated with preeclampsia, from subjects having preeclampsia, with a receiving operating characteristic (ROC) value of at least 0.8.
  • ROC operating characteristic
  • the one or more symptoms associated with preeclampsia are selected from the group consisting of diabetes, higher than normal glucose level, hypertension, excess or sudden weight gain, overweight, obesity, higher than normal body mass index, abnormal weight gain, abnormal blood pressure, water retention, hereditary factors, abnormal proteinurea, headache, edema, abnormal protein/creatinine ratio, abnormal platelet count, stress, nulliparity, abnormal Papanicolaou test results, prior preeclampsia episodes, familial history of PE, renal disease and
  • a test for confirming preeclampsia in a subject wherein the test is able to discern subjects not having preeclampsia but having one or more symptoms associated with preeclampsia, from subjects having preeclampsia, with a sensitivity of at least 80% .
  • a test for confirming preeclampsia in a subject wherein the test is able to discern subjects not having preeclampsia but having one or more symptoms associated with preeclampsia, from subjects having preeclampsia, with specificity of at least 80%.
  • a test for confirming preeclampsia in a subject wherein the test is able to discern subjects not having preeclampsia but having one or more symptoms associated with preeclampsia, from subjects having preeclampsia, with a negative predictive value (NPV) of at least 80%>.
  • NPV negative predictive value
  • preeclampsia are selected from the group consisting of diabetes, higher than normal glucose level, hypertension, excess or sudden weight gain, overweight, obesity, higher than normal body mass index, abnormal weight gain, abnormal blood pressure, water retention, hereditary factors, abnormal proteinurea, headache, edema, abnormal protein/creatinine ratio, abnormal platelet count, stress, nulliparity, abnormal Papanicolaou test results, prior preeclampsia episodes, familial history of PE, renal disease and thrombophilia.
  • a method for confirming preeclampsia comprising performing a test on a sample derived from a female subject wherein the test comprises measuring levels of a plurality of markers and using the levels of the plurality of markers to confirm preeclampsia with a receiving operating characteristic (ROC) value of at least 0.90.
  • ROC receiving operating characteristic
  • a method for confirming preeclampsia comprising performing a test on a sample derived from a female subject wherein the test comprises measuring levels of a plurality of markers and using the levels of the plurality of markers to confirm preeclampsia with a specificity of at least 80%.
  • a method for confirming preeclampsia comprising performing a test on a sample derived from a female subject wherein the test comprises measuring levels of a plurality of markers and using the levels of the plurality of markers to confirm preeclampsia with a sensitivity of at least 80%.
  • a method for confirming preeclampsia comprising performing a test on a sample derived from a female subject wherein the test comprises measuring levels of a plurality of markers and using said levels to confirm preeclampsia with a negative predictive value of at least 80%.
  • test as in any of claims 127-140, wherein the sample is selected from the group consisting of whole blood, urine, serum and plasma.
  • biomarker comprises a biomarker of Group- 1.
  • kits as in any of claims 78, 90 or 95, wherein the biomarker comprises a biomarker of Group- 1.
  • a computer readable medium containing instructions which, when executed by a computer system, cause the computer system to: receive a first data set pertaining to first levels of a plurality of preeclampsia biomarkers in a first biological sample derived from a subject at a first point- in-time;
  • a method for diagnosing or confirming preeclampsia in a subject comprising:
  • detecting protein levels of sFLT, PIG, and a protein or protein fragment binding to pikachurin antibody in a biological sample derived from the subject and calculating a preeclampsia index score using the detected protein levels, wherein the preeclampsia score is indicative of the presence or absence of preeclampsia in the subject.
  • the calculating comprises multiplying the detected protein levels by a unique weight factor, and applying one or more binary functions to weighted detected protein levels.
  • biomarkers selected from the group consisting of sFLT-1, PIGF, abFN, PAPP-A, TakFN, ADAM- 12, and HPX, wherein each of the four or more biomarkers is different from each other.
  • the one or more biomarkers comprise four or more biomarkers, wherein each of the four or more biomarkers is selected from the group consisting of sFLT-1, PIGF, abFN, PAPP-A, TakFN, ADAM- 12, and HPX, wherein each of the four or more biomarkers is different from each other.
  • the two or more biomarkers comprise four or more biomarkers, wherein each of the four or more biomarkers is selected from the group consisting of sFLT-1, PIGF, abFN, PAPP-A, TakFN, ADAM- 12, and HPX, wherein each of the four or more biomarkers is different from each other.
  • the two or more biomarkers comprise four or more biomarkers, wherein each of the four or more biomarkers is selected from the group consisting of sFLT-1, PIGF, abFN, PAPP-A, TakFN, ADAM- 12, and HPX, wherein each of the four or more biomarkers is different from each other.
  • Figure 1 depicts the performance of a series of penalized models with increasing number of markers. The figure shows the mean cross-validated performance
  • Figure 2 depicts the performance of a series of penalized models with increasing number of markers excluding sFlt-l/PlGF. The figure shows the mean cross-validated performance and corresponding standard error. The number on the top represents the size of the model while the arrows identify the models with the highest AUC and the one with mean AUC within 1-se ("1-se" rule for model selection) of the maximum.
  • Figure 3 is a diagram of a duplicate template depicting 32 samples with 2X duplicate Hi and Lo quality control.
  • Figure 4 is a diagram of a triplicate template depicting 20 samples with 3X triplicate Hi and Lo quality control.
  • Figures 5A-5F provide a listing of various PE biomarkers (see also Table 2).
  • Figure 6 is a diagram of an example 20 compound Master Block.
  • preeclampsia diagnosis confirming the presence and/or absence of "pre-eclampsia” or “preeclampsia” or "PE”
  • predicting the likelihood that a subject will develop PE determining and/or confirming the severity of PE
  • determining the susceptibility of a subject not pregnant developing PE if the subject becomes pregnant
  • monitoring PE progression in a subject already diagnosed with PE all with greater sensitivity, specificity, confidence, accuracy, or area under the curve values than traditional PE tests.
  • the methods involve analyzing a sample or samples derived from a subject to confirm presence, absence, quantity and/or conformation of one or more PE biomarkers.
  • a sample derived from the subject can be whole blood, urine, serum, plasma and other liquid samples of biological origin or cells derived therefrom and the progeny thereof. Samples can be manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components.
  • a "marker” or “biomarker” is any biological entity that is represented differently in a sample from an individual that will get or has preeclampsia as compared to an individual that will not get preeclampsia.
  • a biomarker is differently represented if, e.g., it is found in a different level (e.g., amount of protein, R A or DNA), different three dimensional state (native form, mis-folded, alternative conformation), or different arrangements (e.g., complex, aggregates, mis-folded assembles).
  • a PE biomarker can be a protein, a protein fragment, a peptide, a polynucleotide, a gene (DNA) or a gene fragment, an R A transcript, or other forms of R A such as snR A, siRNA and micro-RNA.
  • the terms "protein”, “peptide” and “polypeptide” as used in this application are interchangeable.
  • Polypeptide refers to a polymer of amino acids and includes post-translationally modified polypeptides, glycosylated polypeptide, acetylated polypeptide, phosphorylated polypeptide and the like.
  • PE biomarkers contemplated herein include, but are not limited to the markers listed in Figures 5A-5F (or Table 2).
  • PE profile is the level of one or more preeclampsia biomarkers in a patient sample.
  • PE biomarkers can be determined by measuring protein levels or expression levels.
  • a PE profile can include any one or more of the following sets (panels) of PE biomarkers shown in Table 1.
  • PE profiles include any one or more of the following:
  • ADAM 12 ADAM 12, FN, PAPP-A and HPX.
  • FN • FN, FG and at least one or two biomarkers selected from the group consisting of HPX, sFlt-1, PAPP-A, VEGF (excluding VEGF-Rl), PIGF and ADAM12.
  • VEGF-Rl VEGF-Rl
  • PIGF VEGF-Rl
  • VEGF-Rl VEGF-Rl
  • PIGF VEGF-Rl
  • AD AM12 ADAM12
  • VEGF-Rl VEGF-Rl
  • PIGF VEGF-Rl
  • AD AM12 ADAM12
  • VEGF excluding VEGF-Rl
  • FN FN
  • FG FG
  • HPX FG
  • PAPP-A sFlt-1
  • PIGF PIGF
  • ADAM ADAM
  • P 1 GF in combination with FN, FG, HPX, PAPP-A, sFlt- 1 , VEGF (excluding VEGF-Rl) and/or ADAM 12.
  • ADAM 12 in combination with FN, FG, HPX, PAPP-A, sFlt- 1 , P 1 GF and/or VEGF (excluding VEGF-Rl).
  • any of the PE biomarker profiles or panels herein can optionally exclude one or more of the following biomarkers: ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo- C3), apolipoprotein A-l (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM) and heme.
  • ferritin F
  • CTSB cathepsin B
  • CSC cathepsin C
  • HP haptoglobin
  • A2M alpha-2-macroglobulin
  • A2M apolipoprotein E
  • ApoE apolipoprotein C-III
  • Apo- C3 apolip
  • the panel of biomarkers includes at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or 15 biomarkers.
  • methods of the disclosure comprise determining protein levels of the one or more panels described herein.
  • a panel includes a ratio of sFltl and PIGF
  • the ratio can be of raw levels of sFlt-1 and PIGF, normalized or adjusted levels of sFlt-1 and PIGF (e.g., relative to housekeeping genes, e.g., ABLl, GAPDH, PGKl, or relative to signal across a whole panel), averaged levels, or levels as compared to a control (e.g., purified, recombinant proteins).
  • PE score function provides a single score, e.g., a PE score.
  • a preeclampsia score is a single metric value that represents the one or more preeclampsia biomarkers in a patient sample.
  • the PE score can be reported in a report to the subject or a healthcare service provider of the subject.
  • the PE score can be reported as a PE index.
  • a "PE index” or an “index” is a metric system that indicates the likelihood PE is confirmed, severity of PE or the degree of likelihood of developing PE.
  • the PE index can be calculated from the PE score, using a classification algorithm. Examples of supervised and unsupervised classification processes are described in Jain, "Statistical Pattern Recognition: A Review," IEEE Transactions on Pattern Analysis and Machine Intelligence, Vol. 22, No. 1, January 2000.
  • the PE score or index can be indicative of the diagnosis, prognosis, or confirmation of PE diagnosis.
  • the report can provide, in addition to the PE score or PE index, a set of suggested treatments or assessment of effectiveness of current treatment.
  • diagnosis refers to a determination of whether a subject has or does not have PE.
  • confirming or “confirmation” as used herein generally includes a determination of whether a subject suspected of having PE or previously diagnosed with PE has or does not have PE.
  • prognosing or “prognosis” as used herein generally includes a prediction of the likely course of PE in a subject, such as the likelihood of increasing severity of PE or a subject's responsiveness to treatment.
  • treating or “treatment” as used herein generally means obtaining a desired pharmacologic and/or physiologic effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof (e.g., reducing the likelihood of incidence), reducing the incidence or severity of the disease, and/or therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
  • raw levels of the biomarkers are obtained by obtaining e.g., an optical density (OD) value.
  • the raw data may be used to determine the concentration of a biomarker in a sample using the methods described herein which may include a comparison against a standard curve.
  • the standard curve may have a coefficient of determination.
  • the coefficient of determination may be an R 2 value, for example, an R 2 value of > 0.5, 0.6, 0.7, 0.75, 0.8, 0.85, 0.9 or 0.95 may be used with the methods described herein.
  • the R 2 of a standard curve using the methods described herein is > 0.95. Additional cases of the data may be evaluated using statistical methods known to those of ordinary skill in the art.
  • SoftMax Pro Software such as SoftMax Pro may be used to perform at least some of the calculations and analysis described herein. Acquired data which falls outside of the range of the standard curve will not be analyzed or calculated further.
  • Raw levels of a biomarker can be optionally normalized, e.g., to a blank, a control or to another sample described herein.
  • normalization may include subtracting the OD value of a blank, a control or to another sample from the OD value of the sample. Normalization may also include first taking an average, mean or median of the OD of the sample and second, taking an average, mean or median OD of the blank, control or another sample before subtracting the two OD values.
  • the raw OD values of individual samples, average, mean or median of a set of samples, a blank, a control, another sample, a set of blanks, a set of controls or a set of another samples are log transformed.
  • the log transformation may include a comparison with a standard curve.
  • Biomarker levels can be adjusted relative to one or more of the following: a control derived from a training set as discussed in more detail below, a subject being tested prior to pregnancy, a subject being tested prior to onset of PE, a mean value from pregnant subjects not having PE, a value derived from specified laboratory subjects, a calculated value, a corresponding purified biomarker or a corresponding recombinant biomarker, a control level derived from a sample of a pregnant subject that does not have PE or does not have symptoms of PE, control level derived from a sample of a pregnant subject that is not diagnosed as having PE or does not have symptoms of PE, a control level derived from a sample of a pregnant subject that has (or is diagnosed as having) symptoms of PE, such as complications of pregnancy symptoms, but does not have (or is not diagnosed as having) PE, a control level derived from a sample of a pregnant subject that does not have PE but has one or more preeclampsia symptoms (e.g., a pregnant subject
  • Pap smear prior preeclampsia episodes (e.g., personal history of PE), familial history of PE, PE in prior pregnancies, renal disease, thrombophilia, or any combination thereof; a control level derived from a sample of a pregnant subject that is not diagnosed with PE but has one or more preeclampsia symptoms (e.g., a pregnant subject having complicated pregnancy) such as those mentioned above.
  • the training set can be based on a theoretical model, real (measured) values obtained from subjects, or a combination of both.
  • a training set is based on real values obtained from at least 10, 50, 100, 150, 200, 250, 300, 400, or 500 subjects. More preferably, at least 5, 10, 20, 30, 40, 50, or 60% of the subjects in the training set have PE while the remaining subjects are pregnant and do not have PE.
  • PE biomarker levels are adjusted by multiplying each biomarker level (or normalized level) by a weighting factor, or "weight”, to arrive at weighted levels.
  • a biomarker score or biomarker index is then calculated using an algorithm, a function, a real function, a polynomial or the like.
  • Such algorithm is referred to herein as PE score function.
  • the weight for each biomarker in the PE score function can be unique.
  • the weight for each biomarker can be a positive or a negative real number.
  • the weight can be a ratio of two or more biomarkers.
  • the PE score function can be a real function algorithm comprising binary operations such as addition, subtraction, multiplication and division.
  • the PE score function comprises at most one, two, three, four, five, six or seven binary operations.
  • all binary operations are additions or subtractions of variables (the variables being biomarker values whether adjusted or non-adjusted).
  • the binary operations include at least one division of variables.
  • the binary operations include only one division of variables.
  • the binary operations exclude division of variables.
  • the binary operations exclude multiplication of variables.
  • PE score functions can be linear, exponential, logarithmic, quadratic, or any combination thereof.
  • a PE score function for determining a PE score can be represented according to the following formula:
  • PE Score a 0 + ai(ratio) + a 2 (sFLT-l) + a 3 (PlGF) + a 4 (FNl) + a 5 (FN2) + a 6 (PAPPA) +a 7 (HPX) +ag(ADAM12) + ag(FG) + a n (biomarker or ratio of biomarkers selected from Table 1), wherein, (i) a 0 is zero or at most -0.5, -1, -5, -10, -20, -30, -40, -50, -60, -70, -80, -90, - 100, -110, -120, -130, -140, or -150 or a 0 is zero, (ii) ai is at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.10 , (iii) a 2 is zero or at least -5.0, -4.0,
  • L -87.8431 + 0.0422(ratio) + 0.9659(HPX) + 6.3886(FN1).
  • L -86.8431 +
  • Weighted levels of all biomarkers in a panel can then be totaled and in some cases, such as in the levels of sFlt and P1GF, the weighted levels can be formed into a ratio. The sum of the weighted levels and optionally a ratio results in a single weighted level or "PE score".
  • Each biomarker can have a unique weighting factor, or a combination of biomarkers can have a unique weighting factor.
  • a preeclampsia score may be determined by methods similar to those described for a preeclampsia signature, e.g. the levels of each of the one or more preeclampsia markers in a patient sample may be log 2 , log e or logio transformed and normalized as described above for generating a preeclampsia profile.
  • the weighted levels for calculating the score can be defined by a reference dataset, "training dataset,” or “training set.”
  • the training set can be based on a model, actual values obtained from subjects, or a combination thereof.
  • a training set can comprise subjects diagnosed as having symptoms of PE.
  • a training set can comprise subjects having symptoms of PE, but not PE.
  • a training set can comprise subjects having symptoms of PE, but not PE, and having one or more other disorders (e.g., subjects having pregnancies with
  • diabetes e.g., gestational, type I or type II
  • hypertension e.g., chronic or non-chronic
  • normal weight e.g., a weight gain, abnormal blood pressure, water retention, hereditary factors, abnormal proteinurea, headache, edema, abnormal protein/creatinine ratio, abnormal platelet count, stress, nulliparity, abnormal
  • a training set can comprise subjects diagnosed as having PE with one or more disorders (e.g., subjects having pregnancies with complications) such as diabetes (e.g., gestational, type I or type II), higher than normal glucose level, hypertension (e.g., chronic or non-chronic), higher than normal, obesity, higher than normal body mass index (BMI), abnormal weight gain, abnormal blood pressure, water retention, hereditary factors, abnormal proteinurea, headache, edema, abnormal protein/creatinine ratio, abnormal platelet count, stress, nulliparity, abnormal Papanicolaou test results (Pap smear), prior preeclampsia episodes (e.g., personal history of PE), familial history of PE, PE in prior pregnancies, renal disease, thrombophil
  • the training set can include at least 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, or 400 subjects.
  • the training set can include data from at least 15, 50, 100, 150, 200 or 250 subjects having a normal pregnancy, and at least 15, 50, 100, 150, 200 or 250 pregnant subjects with PE. In some instances, more than 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50% of the preeclamptic subjects have at least one additional condition (e.g., hypertension, diabetes, overweight, etc.).
  • the classification of PE that is used to provide the "preeclampsia index" described herein is not based on for example blood pressure, weight gain, water retention, hereditary factors, proteinurea, headache, edema, protein/creatinine ratio, platelet count, stress, PE in prior pregnancies, nulliparity, age, age less than 20 years, age greater than 35, race, African- American and Filipino decent, serotype, Papanicolaou test results (Pap smear), prior preeclampsia episodes (e.g., personal history of PE), familial history of PE, number of pregnancies, number of miscarriages, body mass index (BMI), gestational diabetes, type I diabetes, obesity, glucose level, current and past medications, stress, PE in prior pregnancies (of the subject or her family members), chronic hypertension, renal disease and thrombophilia.
  • blood pressure e.g., blood pressure, weight gain, water retention, hereditary factors, proteinurea, headache, edem
  • the classification of PE is not based on any of the characteristics of pregnancy just mentioned. In some examples, the classification of PE is based on at least one of the characteristics of pregnancy just mentioned. In some cases, the PE index may be based on the female subject's gestational period.
  • a "report,” as described herein, is an electronic or tangible document which includes report elements that provide information relating to a subject.
  • a subject report optionally includes one or more of the following: information about the subject, a PE profile, a PE score, a PE index, PE confirmation, PE diagnosis, PE prognosis, PE monitoring status, and/or suggested treatments.
  • a subject report can further include one or more of: 1) information regarding the testing facility; 2) service provider information; 3) patient data; 4) sample data; 5) an assessment report, which can include various information including: a) reference values employed, and b) test data, where test data can include, e.g., a protein level determination; and 6) other features.
  • the report may be for positive confirmation of PE, negative confirmation of PE, diagnosis of PE, characteristics of PE, progress of PE, severity of PE, or prognosis of PE.
  • Positive confirmation of PE refers to a situation where a subject having PE symptoms is confirmed as having PE.
  • Negative confirmation of PE refers to a situation where a subject not having symptoms of PE is confirmed as not having PE.
  • Such report may include relative weight or signature values of biomarkers, PE score or PE index score.
  • the report may include recommendation as to treatment recommendations (e.g., bed-rest, aspirin, drinking extra water, a low salt diet, medicines to control blood pressure, corticosteroids, or recommendation for early delivery).
  • sample encompasses blood, urine, serum, plasma, and other liquid samples of biological origin or cells derived therefrom. Once a sample is derived from a subject, it can be used directly, frozen, or maintained in appropriate culture medium for short periods of time. A sample that is derived from blood may be allowed to clot, and the serum separated and collected to be used in the assay.
  • a sample volume of blood, serum, or urine between 2 ⁇ 1 to 2,000 ⁇ 1, may be sufficient for determining the PE score.
  • the sample volume ranges from ⁇ to 1,750 ⁇ 1, from 20 ⁇ 1 to 1,500 ⁇ 1, from 40 ⁇ 1 to 1,250 ⁇ 1, from 60 ⁇ 1 to ⁇ , ⁇ , from ⁇ to 900 ⁇ , from 200 ⁇ 1 to 800 ⁇ 1, from 400 ⁇ 1 to 600 ⁇ 1.
  • a sample volume is 2-lOmL or 0.5-5 mL or up to 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mL.
  • a subject analyzed may have zero, or at least one, two, three, four, or five factors which confound a diagnosis of preeclampsia.
  • a confounding factor may be selected from the group consisting of: high blood pressure, age over 35 years, higher than normal weight, quick weight gain, gestational period greater than 20 weeks, ethnicity, diabetes (Type I or II), high proteinurea, kidney disease, autoimmune disease, prior PE by the subject in an earlier pregnancy, and a family or maternal history of PE.
  • a sample from a subject is evaluated to obtain a representation of the level(s) of one or more PE biomarkers.
  • the levels of one or more PE biomarkers can be used to provide, for example, a PE profile, PE signature, PE score, or PE index as described in greater detail below.
  • a subject sample may be treated in a variety of ways so as to enhance detection of the preeclampsia marker.
  • the red blood cells may be removed from the sample (e.g., by centrifugation) prior to assaying.
  • Such a treatment may serve to reduce the non-specific background levels of detecting the level of a preeclampsia marker using an affinity reagent.
  • Detection of a preeclampsia marker may also be enhanced by concentrating the sample using procedures well known in the art (e.g., acid precipitation, alcohol precipitation, salt precipitation, hydrophobic precipitation, filtration (using a filter which is capable of retaining molecules greater than 30 kD, e.g., Centrim 30TM) or affinity purification.
  • the pH of the test and control samples will be adjusted to, and maintained at, a pH which approximates neutrality (e.g., pH 6.5-8.0). Such a pH adjustment will prevent complex formation, thereby providing a more accurate quantitation of the level of marker in the sample.
  • the pH of the sample is adjusted and the sample is concentrated in order to enhance the detection of the marker. pH may be adjusted using methods known to those of ordinary skill in the art, for example, adding an acid to a basic or neutral pH sample or adding a base to an acidic or neutral pH sample.
  • Buffers and/or other reagents may be added to the sample to facilitate preparation of the sample prior to determining a level of at least one biomarker in the sample.
  • a buffer and/or other reagent may include at least, but is not limited to, one of the following: ethylenediaminetetraacetic acid (EDTA), phosphate buffered saline, Hanks balanced salt solution, Ficoll, sodium chloride, sodium citrate, silica, thrombin, tehophylline, adenosine, dipyridamole, aprotinine, heparin, lithium heparin, fluoride, potassium oxalate, tri-sodium citrate, citric acid, and/or dextrose.
  • the buffer and/or other reagent may be compounded in an inert base, for example, a gel, water, saline or the like.
  • a sample of blood may be collected using a serum separator tube (SST).
  • SST serum separator tube
  • the SST may contain a buffer and/or other reagent.
  • a sample of blood may be collected using a clot-2 serum separator tube which may contain a buffer and/or reagent.
  • the SST and/or clot-2 tube may be obtained from a manufacturer such as Becton Dickenson although any comparable tube may be used.
  • the sample may be treated using a method, reagent or chemical known to one of ordinary skill in the art such that components of the sample become separated from one another.
  • the sample of blood is separated such that the serum is in a layer comprising the top of the sample.
  • a subject sample is typically obtained from the individual during the second or third trimester of gestation.
  • gestation it is meant the duration of pregnancy in a mammal, e.g., the period of development in the uterus from conception until birth.
  • a subject sample may be derived early in gestation, for example, on or before 34 weeks of gestation, e.g., at weeks 20-34 of gestation, at 24-34 weeks of gestation, at weeks 30-34 weeks of gestation.
  • a subject sample may be derived late in gestation, for example, after 34, 35, 36, 37, or 38 weeks of gestation.
  • a PE profile, signature, score, or index may be determined soon after or at least 2, 3, or 4, weeks from the time a sample is derived from a subject. In some cases, a PE profile, signature, score, or index is determined at most 1, 2, 3, or 4 days from the time a sample is derived from a subject.
  • the sample can be processed (e.g., plasma or serum isolated).
  • the sample, or portion thereof can further be diluted.
  • a sample, or portion of a sample can be diluted by a factor of at least 5, 10, 50, 100, 500, 1,000, 5,000, 10,000, 15,000, 20,000, 30,000, 35,000, 40,000, 45,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000 or 80,00 fold.
  • a biomarker is a differentially expressed protein level
  • the biomarker can be detected by measuring the levels or the amounts of one or more proteins, protein fragments, peptides, nucleic acid transcripts (e.g. mR A), genes, or gene fragments.
  • Each biomarker assayed using the methods and protocols described herein may have a threshold. Often the threshold of a biomarker is the performance of a biomarker in an assay, method or protocol. In some cases, the methods, protocols and assays described herein may be accurate, sensitive, and specific and may be used as a positive or a negative predictive value. The methods, protocols and assays described herein may be at least 70%, 75%, 80%>, 85%o, 90%o, 95%) or 99% accurate. The methods, protocols and assays described herein may be at most 70%, 75%, 80%, 85%, 90%, 95% or at most 99% accurate.
  • the methods, protocols and assays described herein may be at least 70%>, 75%, 80%>, 85%, 90%, 95% or 99% sensitive.
  • the methods, protocols and assays described herein may be at most 70%, 75%, 80%, 85%, 90%, 95% or about 99% sensitive.
  • the methods, protocols and assays described herein may be at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or more specific.
  • the methods, protocols and assays described herein may be at most 70%, 75%, 80%, 85%, 90%), 95%), 99%) or less specific.
  • the methods, protocols and assays described herein may have a positive predictive value of at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or more.
  • the methods, protocols and assays described herein may have a positive predictive value of at most 70%, 75%, 80%, 85%, 90%, 95%, 99% or less.
  • the methods, protocols and assays described herein may have a negative predictive value of at least 70%, 75%, 80%, 85%, 90%, 95%), 99%) or more.
  • the methods, protocols and assays described herein may have a negative predictive value of at most 70%, 75%, 80%, 85%, 90%, 95%, 99% or less.
  • a biomarker assayed using the methods and protocols described herein may be present in a sample above the lowest concentration of a standard curve sample. In other cases, a biomarker assayed using the methods and protocols described herein may be present in a sample below the lowest concentration of a standard curve sample. In some cases, a biomarker assayed using the methods and protocols described herein may be present in a sample above the highest concentration of a standard curve sample. In other cases, a biomarker assayed using the methods and protocols described herein may be present in a sample below the highest concentration of a standard curve sample.
  • a biomarker assayed using the methods and protocols described herein may be present in a sample above the lowest concentration of a high quality control sample. In other cases, a biomarker assayed using the methods and protocols described herein may be present in a sample below the lowest concentration of a high quality control sample. In some cases, a biomarker assayed using the methods and protocols described herein may be present in a sample above the highest concentration of a high quality control sample. In other cases, a biomarker assayed using the methods and protocols described herein may be present in a sample below the highest concentration of a high quality control sample.
  • a biomarker assayed using the methods and protocols described herein may be present in a sample above the lowest concentration of a low quality control sample. In other cases, a biomarker assayed using the methods and protocols described herein may be present in a sample below the lowest concentration of a low quality control sample. In some cases, a biomarker assayed using the methods and protocols described herein may be present in a sample above the highest concentration of a low quality control sample. In other cases, a biomarker assayed using the methods and protocols described herein may be present in a sample below the highest concentration of a low quality control sample.
  • a level of a biomarker assayed using the methods and protocols described herein may increase between a first assay and a second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may increase by about two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500 or 10 000 fold between the first assay and the second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may increase by at least two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500, 10,000 fold or more between the first assay and the second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may increase by at most two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500 or less than 10 000 fold between the first assay and the second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may decrease between a first assay and a second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may decrease by about two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500 or 10 000 fold between the first assay and the second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may decrease at least two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500 or 10 000 fold or more between the first assay and the second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may decrease at most two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500, 10 000 fold or less, between the first assay and the second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may increase between a first assay and a second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may increase by about two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500 or 10 000 percent between the first assay and the second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may increase at least by two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500 or 10 000 percent or more between the first assay and the second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may increase by at most two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500 or 10 000 percent or less, between the first assay and the second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may decrease between a first assay and a second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may decrease by about two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500 or 10 000 percent between the first assay and the second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may decrease by at least two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500, 10 000 percent or more between the first assay and the second assay.
  • a level of a biomarker assayed using the methods and protocols described herein may decrease by at most two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 5000, 7500 or 10 000 percent or less, between the first assay and the second assay.
  • Clinical measures may be associated with, but are not limited to, total blood pressure, diastolic blood pressure, systolic blood pressure, mean arterial blood pressure, proteinurea detected by, for example, dipstick method or 24-hour collection method, body mass index, swelling, abdominal pressure, uterine pulsatility index, uterine Doppler measurements, circulating free DNA, circulating free fetal DNA, fetal DNA and/or thrombocytopenia, fetal abnormalities, gestational period, age of mother, previous case of preeclampsia during pregnancy, race or ethnicity, history of preeclampsia with mother or farther, multiple births, first birth, and subject's smoking history.
  • the disclosure provides a method for diagnosing or confirming an existence of preeclampsia in a subject comprising: performing at least two different assays that determine a level of fibronectin in a sample from the subject; and evaluating the sample and using the levels from the plurality of assays to diagnose or confirm the existence of preeclampsia and calculate an index.
  • the method further comprises, based upon the index, suggesting a treatment for preeclampsia, the treatment selected from the group consisting of aspirin, preterm labor or bedrest.
  • the disclosure provides a method for diagnosing or confirming an existence of preeclampsia in a subject comprising: evaluating a level of a ratio of sFlt-1 and P1GF and a level of a plurality of biomarkers in a sample derived from the subject, wherein the different biomarker is not ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-1 (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM), free human chorionic gonadotropin (free beta hCG) or heme; and evaluating the sample and using the levels from the previous step to determine
  • the method further comprises, based upon the index, suggesting a treatment for preeclampsia, the treatment involving aspirin, preterm labor or bedrest. In some cases, the method further comprises performing replicates of identical assays for each biomarker using the sample. In some cases, the method further comprises determining a mean level for each of the biomarkers using levels derived from each of the multiple identical assays. In some cases, the method further comprises performing a log 2 , log e or logio transformation of the mean levels. In some cases, the method further comprises comparing the levels of each biomarker to a standard curve for that biomarker.
  • the method further comprises weighting each of the biomarkers, wherein the weighting includes providing numbers into a polynomial such that each marker has a distinct weight.
  • the calculating comprises determining a ratio of adjusted levels of sFlt-1 and P IGF. In some cases, the calculating comprises determining a ratio of normalized levels of sFlt-1 and P1GF. In some cases, the calculating comprises determining a ratio of raw levels of sFlt-1 and PIGF. In some cases, the calculating comprises determining a ratio of adjusted levels of sFlt-1 and PIGF compared to a control.
  • the calculating comprises determining a ratio of normalized levels of sFlt-1 and PIGF compared to a control. In some cases, the calculating comprises determining a ratio of raw levels of sFlt-1 and PIGF compared to a control.
  • the disclosure provides a method for diagnosing or confirming an existence of preeclampsia in a subject comprising: evaluating a level of a ratio of sFlt-1 and PIGF and a level of a plurality of biomarkers in a sample derived from the subject, wherein the different biomarker is not ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-1 (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM), free human chorionic gonadotropin (free beta hCG) or heme; and evaluating the sample and using the levels from step (a) to
  • the plurality of biomarkers is selected from the group consisting of sFlt- 1 ,P 1 GF, FN and PAPP-A; sFlt- 1 , P 1 GF, FN, ADAM 12 and PAPP-A; sFlt-1, PIGF, PAPP-A and FN; sFlt-1, PIGF, HPX, FN and PAPP- A; PIGF, ADAM 12, FN and PAPP-A; PIGF, FN and PAPP-A; sFlt-1, PIGF and FN; PIGF, FN and PAPP-A; sFlt-1, PIGF, FN and ADAM 12; sFlt-1, PIGF and FN; PIGF, sFlt-1 and FN; sFlt-1, FN and ADAM 12; sFlt-1, PIGF and FN; PIGF, sFlt-1 and FN; sFlt-1, FN
  • the method further comprises, based upon the index, suggesting a treatment for preeclampsia, the treatment involving aspirin, preterm labor or bedrest. In some cases, the method further comprises performing replicates of identical assays for each biomarker using the sample. In some cases, the method further comprises determining a mean level for each of the biomarkers using levels derived from each of the multiple identical assays. In some cases, the method further comprises performing a log 2 , log e or logio transformation of the mean levels. In some cases, the method further comprises comparing the levels of each biomarker to a standard curve for that biomarker.
  • the method further comprises weighting each of the biomarkers, wherein the weighting includes providing numbers into a polynomial such that each marker has a distinct weight.
  • the calculating comprises determining a ratio of adjusted levels of sFlt-1 and PIGF. In some cases, the calculating comprises determining a ratio of normalized levels of sFlt-1 and PIGF. In some cases, the calculating comprises determining a ratio of raw levels of sFlt-1 and PIGF. In some cases, the calculating comprises determining a ratio of adjusted levels of sFlt-1 and PIGF compared to a control.
  • the calculating comprises determining a ratio of normalized levels of sFlt-1 and PIGF compared to a control. In some cases, the calculating comprises determining a ratio of raw levels of sFlt-1 and PIGF compared to a control.
  • the disclosure includes detection reagents and antibodies that may be used to determine levels of a plurality of biomarkers disclosed herein.
  • the detection reagents may include reagents useful for performing an ELISA.
  • Examples of commercially available antibody kits that can be used in an ELISA protocol include, but are not limited to, anti-PlGF (distributed by USCN Life Science Inc., Roche and R&D Systems), anti-sFlt-1 (distributed by Boster Bio., R&D systems,
  • anti- PAPP-A (distributed by R&D systems, RayBioTech, IBL Japan, DRG International, Abnova, USCN Life Science, Novus Bio, Rapid Test, MyBioSource, antibodies-online.com, Fisher Scientific, elabscience, Sigma Aldrich, C USA Bio, ANSH Labs, Demeditec, Alpco, AMS Bio, NovaTeinBio, Creative Biomart, Biorbyt, Biomatic Corporation), anti-VEGF (distributed by AMS Bio, Mybiosource, Abnova, antibodies- online.com, United States Biological, Biomatik Corporation, Cloud-Clone Corp, Biovendor, Boster Immunoleader, Enzo Life Sciences, Fitzgerald, Abnova, Aviva Systems Biology and Creative Biomart), anti-fibronectin (distributed by Biovendor, Boster Immunoleader, QED Bioscience, eBioscience, Biorbyt, Fitzgerald, Amsbio, MyBioSource, Nova TeinBio, Abnova, Aviva Systems Biology, Creative Biomart, antibodies-online.com,
  • the methods include detecting the levels of one biomarker described herein using one ELISA kit and/or antibody described herein. In some cases, the methods include detecting the levels of one biomarker described herein using two ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of one biomarker described herein using three ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of one biomarker described herein using four ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of one biomarker described herein using five ELISA kits and/or antibodies described herein.
  • the methods include detecting the levels of one biomarker described herein using more than five ELISA kits and/or antibodies described herein. Often the one biomarker is independently measured using one, two, three, four, five or more than five ELISA kits. In some cases, the one, two, three, four, five or more than five ELISA kits may be the same or different ELISA kits.
  • the methods include detecting the levels of two biomarkers described herein using two ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of two biomarkers described herein using three ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of two biomarkers described herein using four ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of two biomarkers described herein using five ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of two biomarkers described herein using more than five ELISA kits and/or antibodies described herein. Often the two biomarkers are independently measured using two, three, four, five or more than five ELISA kits. In some cases, the two, three, four, five or more than five ELISA kits may be the same or different ELISA kits.
  • the methods include detecting the levels of three biomarkers described herein using three ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of three biomarkers described herein using four ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of three biomarkers described herein using five ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of three biomarkers described herein using more than five ELISA kits and/or antibodies described herein. Often the three biomarkers are independently measured using three, four, five or more than five ELISA kits. In some cases, the three, four, five or more than five ELISA kits may be the same or different ELISA kits.
  • the methods include detecting the levels of four biomarkers described herein using four ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of four biomarkers described herein using five ELISA kits and/or antibodies described herein. In other cases, the methods include detecting the levels of four biomarkers described herein using more than five ELISA kits and/or antibodies described herein. Often the four biomarkers are independently measured using four, five or more than five ELISA kits. In some cases, the four, five or more than five ELISA kits may be the same or different ELISA kits.
  • the antibodies against the selected biomarkers may be monoclonal antibodies. In some cases the antibodies against the selected biomarkers may be polyclonal antibodies. Of particular interest are antibodies against a plurality biomarkers selected from a group consisting of P IGF, HPX, sFlt-1, PAPP-A, VEGF (excluding VEGF-Rl), FN, FG, and ADAM 12. Such antibodies may be monoclonal or polyclonal antibodies. Such antibodies may be commercially available or generated by the user using methods known to those of ordinary skill in the art.
  • any commercially available antibody known to one of ordinary skill in the art may be used to detect a biomarker listed herein and may be used in combination with the subject methods.
  • commercially available antibodies can include, but are not limited to, anti-PlGF (distributed by Amb, Novus Biologicals, Nordic Biosite or Tebu Biologicals), anti-HPX (distributed by Sino Biological, Pierce, Sigma Aldrich, Origene, Lifespan, Proteintech Group, AbD Sertotec, BioRad, ThermoFisher, Agrisera, Angio-Proteomie, Enzo Life Sciences, Aviva Systems Biology, Everest Biotech, R&D systems, St. John's
  • Monoclonal antibodies that specifically bind to any of the biomarkers listed herein may be produced using methods known to those of ordinary skill in the art. These methods include the methods of Kohler and Milstein (Nature, 256: 495-497, 1975 ) and Campbell ("Monoclonal Antibody Technology, The Production and Characterization of Rodent and Human Hybridomas" in Burdon et al., Eds., Laboratory Techniques in Biochemistry and Molecular Biology, Volume 13, Elsevier Science Publishers, Amsterdam, 1985 ), as well as methods described by Huse et al. (Science, 246, 1275-1281, 1989 ).
  • Monoclonal antibodies may be prepared from supernatants of cultured hybridoma cells or from ascites induced by intra-peritoneal inoculation of hybridoma cells into mice. These methods are described in Kohler and Milstein (Eur. J. Immunol, 6, 511-519, 1976). The route and schedule of immunization of the host animal or cultured antibody-producing cells may follow with route and schedules known to those of ordinary skill in the art for antibody stimulation and production. Typically, mice are used as the test model, however, any mammalian subject or antibody producing cells therefrom can be used for production of mammalian, including human, hybrid cell lines.
  • immune lymphoid cells can be fused with myeloma cells to generate a hybrid cell line that can be cultured indefinitely, to produce monoclonal antibodies.
  • lymphocytes may be selected for fusion and may be isolated either from lymph node tissue or the spleens of immunized animals.
  • Murine myeloma cell lines can be obtained, for example, from the American Type Culture Collection (ATCC; Manassas, VA). Human myeloma and mouse-human heteromyeloma cell lines have also been described (Kozbor et al., J. Immunol., 133:3001-3005, 1984; Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, pp. 51-63, 1987).
  • the hybrid cell lines can be maintained in vitro and stored and preserved in any number of conventional ways, including freezing and storage under liquid nitrogen. Frozen cell lines can be revived and cultured indefinitely.
  • the secreted antibody can be recovered from tissue culture supernatant by conventional methods such as precipitation, ion exchange chromatography, affinity chromatography, or the like.
  • the antibody may be from any of one of the following immunoglobulin classes: IgG, IgM, IgA, IgD, or IgE, and the subclasses thereof, and preferably is an IgG antibody.
  • a first antibody set may be included, that is specifically designed to interact with selected biomarkers.
  • the first antibody set may be designed to interact with proteins selected from the group consisting of P IGF, HPX, sFlt-1, PAPP-A, VEGF (excluding VEGF-R1), FN, FG, and ADAM 12.
  • detection reagents other than antibodies may be used to practice the methods described herein.
  • a detection reagent specifically binds to a biomarker as described herein.
  • detection reagents may further comprise aptamers, Fc fragments, Fab fragments, Fab2 fragments, ScFv domains, diabodies, non-antibody ligands, small molecules, peptides, polypeptides, proteins, nanoparticles, affibodies or the like.
  • the disclosure provides a method for diagnosing or confirming a presence of preeclampsia in a subject comprising: performing at least two different assays that determine a level of fibronectin in a sample derived from the subject; and evaluating the sample and using the levels from the plurality of assays to diagnose or confirm the presence of preeclampsia and calculate an index.
  • the method further comprises, based upon the index, suggesting a treatment for preeclampsia, the treatment involving aspirin, preterm labor or bedrest.
  • the disclosure provides a method for diagnosing or confirming an existence of preeclampsia in a subject comprising: measuring a level of a ratio of sFlt-1 and P1GF and a level of a plurality of biomarkers in a sample derived from the subject, wherein none of the biomarkers is ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-l (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM), free human chorionic gonadotropin (free beta hCG) or heme; and evaluating the sample and using the levels from the first step to determine
  • the method further comprises step, based upon the index, suggesting a treatment for preeclampsia, the treatment involving aspirin, preterm labor or bedrest.
  • the method further comprises performing replicates of identical assays for each biomarker using the sample.
  • the method further comprises determining a mean level for each of the biomarkers using levels derived from each of the multiple identical assays.
  • the method further comprises performing a log 2 , log e or logio transformation of the mean levels.
  • the method further comprises comparing the levels of each biomarker to a standard curve for that biomarker.
  • the method further comprises weighting each of the biomarkers, wherein the weighting includes providing numbers into a polynomial such that each marker has a distinct weight.
  • the calculating comprises determining a ratio of adjusted levels of sFlt-1 and P IGF. In some cases, the calculating comprises determining a ratio of normalized levels of sFlt-1 and P1GF. In some cases, the calculating comprises determining a ratio of raw levels of sFlt-1 and P1GF. In some cases, the calculating comprises determining a ratio of adjusted levels of sFlt-1 and P1GF compared to a control.
  • the calculating comprises determining a ratio of normalized levels of sFlt-1 and P1GF compared to a control. In some cases, the calculating comprises determining a ratio of raw levels of sFlt-1 and P1GF compared to a control.
  • the disclosure provides a method for diagnosing or confirming a presence of preeclampsia in a subject comprising: measuring a level of a ratio of sFlt-1 and PIGF and a level of a plurality of biomarkers in a sample derived from the subject, wherein none of the biomarkers is ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-1 (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM), free human chorionic gonadotropin (free beta hCG) or heme; and evaluating the sample and using the levels from the first step to determine
  • the plurality of biomarkers is selected from the group consisting of sFlt-l,PlGF, FN and PAPP-A; sFlt-1, PIGF, FN, ADAM 12 and PAPP-A; sFlt-1, PIGF, PAPP-A and FN; sFlt-1, PIGF, HPX, FN and PAPP-A; PIGF, ADAM 12, FN and PAPP-A; PIGF, FN and PAPP-A; sFlt-1, PIGF and FN; PIGF, FN and PAPP-A; sFlt-1, PIGF, FN and ADAM 12; sFlt-1, PIGF and FN; PIGF, sFlt-1 and FN; sFlt-1, FN and ADAM 12; sFlt-1, PIGF and FN; PIGF, sFlt-1 and FN; sFlt-1, FN and ADAM 12;
  • the method further comprises, based upon the index, suggesting a treatment for preeclampsia, the treatment involving aspirin, preterm labor or bedrest. In some cases, the method further comprises performing replicates of identical assays for each biomarker using the sample. In some cases, the method further comprises determining a mean level for each of the biomarkers using levels derived from each of the multiple identical assays. In some cases, the method further comprises performing a log 2 , log e or logio transformation of the mean levels. In some cases, the method further comprises comparing the levels of each biomarker to a standard curve for that biomarker.
  • the method further comprises weighting each of the biomarkers, wherein the weighting includes providing numbers into a polynomial such that each marker has a distinct weight.
  • the calculating consisting of determining a ratio of adjusted levels of sFlt-1 and PIGF. In some cases, the calculating consisting of determining a ratio of normalized levels of sFlt-1 and PIGF. In some cases, the calculating consisting of determining a ratio of raw levels of sFlt-1 and PIGF. In some cases, the calculating consisting of determining a ratio of adjusted levels of sFlt-1 and PIGF compared to a control.
  • the calculating consisting of determining a ratio of normalized levels of sFlt-1 and PIGF compared to a control. In some cases, the calculating consisting of determining a ratio of raw levels of sFlt-1 and P1GF compared to a control.
  • Means for assaying protein or peptide levels include, but are not limited to, enzyme immunoassays (EIA) such as enzyme multiplied immunoassay technique (EMIT), enzyme- linked immunosorbent assay (ELISA), sandwich ELISA, competitive ELISA, IgM antibody capture ELISA (MAC ELISA), and microparticle enzyme immunoassay (MEIA); capillary electrophoresis immunoassays (CEIA), radioimmunoassays (RIA); immunoradiometric assays (IRMA); fluorescence polarization immunoassays (FPIA), or chemiluminescence assays (CL).
  • EIA enzyme multiplied immunoassay technique
  • ELISA enzyme- linked immunosorbent assay
  • sandwich ELISA sandwich ELISA
  • competitive ELISA IgM antibody capture ELISA
  • MEIA microparticle enzyme immunoassay
  • CEIA capillary electrophoresis immunoassays
  • RIA radioi
  • Immunoassays can also be used in conjunction with laser induced fluorescence.
  • Liposome immunoassays such as flow-injection liposome immunoassays and liposome immunosensors, are also suitable for use in the present disclosure.
  • nephelometry assays in which the formation of protein/antibody complexes results in increased light scatter that is converted to a peak rate signal as a function of the marker concentration, are suitable for use in the methods of the present disclosure.
  • ELISA assay methodology is competitive ELISA.
  • an antibody to the target is first exposed with a labeled target (e.g., biotinylated hemopexin).
  • the antibody is subsequently exposed to the unlabeled target (e.g., hemopexin).
  • the labeled target e.g., biotinylated hemopexin
  • the unlabeled target e.g., hemopexin
  • both sets of targets compete for binding sites on the antibody. The more targets that are available, the fewer the amount of labeled targets that bind to the antibodies. Subsequently, the detectable signal from the labeled target will be detected.
  • the labels can include, among others,
  • radioisotopes for example C, H, P, p, s, I and I
  • fluorescers for example C, H, P, p, s, I and I
  • phosphoroscers for example C, H, P, p, s, I and I
  • chemiluminescers for example C, H, P, p, s, I and I
  • chromogenic dyes for example C, H, P, p, s, I and I
  • fluorescers for example C, H, P, p, s, I and I
  • phosphoroscers for example C, H, P, p, s, I and I
  • chromogenic dyes for example C, H, P, p, s, I and I
  • enzymes for example C, H, P, p, s, I and I
  • antibodies for example C, H, P, p, s, I and I
  • particles such as magnetic particles, quantum dots, heavy elements, nuclear magnetic resonance (NMR
  • conjugates include, but are not limited to calmodulin binding protein (CBP) and calmodulin, a combination of biotin and avidin, a combination of biotin and streptavidin, a combination of biotin and NeutrAvidin®, a combination of biotin and human-derived biotin-binding molecules, a combination of biotin and Strep-Tactin®, a combination of Strep-Tag® and Strep-Tactin®, a combination of Strep-Tagil® and Strep-Tactin ®, a combination of S-Tag® and S-protein, a combination of Halo Ligand® and Halotag®, a combination of glutathione and glutathione S- transferase, a combination of amylose and a maltose-binding protein, a combination of appropriately designed epitope and a humanized monoclonal antibody for the epitope, and a combination of appropriately designed sugar chains and relevant sugar chain-recognizing molecules including
  • Antigens-antibodies conjugates include for example, digoxigenin/anti-digoxigenin, dinitrophenyl (DNP) and anti- DNP, dansyl-X-anti-dansyl, Fluorescein and anti-fluorescein, lucifer yellow and anti-lucifer yellow, rhodamine and anti-rhodamine, and other conjugates known in the art.
  • Other suitable binding pairs may include polypeptides such as the FLAG-peptide [Hopp et al,
  • one or more antibodies specific for the proteins of interest may be immobilized onto a selected solid surface, preferably a surface exhibiting a protein affinity such as the wells of a polystyrene microtiter plate.
  • a non-specific "blocking" protein that is known to be antigenically neutral with regard to the test sample such as bovine serum albumin (BSA), casein or solutions of powdered milk. This allows for blocking of non-specific adsorption sites on the test sample such as bovine serum albumin (BSA), casein or solutions of powdered milk.
  • BSA bovine serum albumin
  • immobilizing surface is contacted with the sample to be tested under conditions that are conducive to immune complex (antigen/antibody) formation.
  • Such conditions include diluting the sample with diluents such as BSA or bovine gamma globulin (BGG) in phosphate buffered saline (PBS)/Tween or PBS/Triton-X 100, which also tend to assist in the reduction of nonspecific background, and allowing the sample to incubate for about 2-4 hours at temperatures on the order of about 25°-27°C (although other temperatures may be used). Following incubation, the antisera-contacted surface is washed so as to remove non immunocomplexed material.
  • diluents such as BSA or bovine gamma globulin (BGG) in phosphate buffered saline (PBS)/Tween or PBS/Triton-X 100, which also tend to assist in the reduction of nonspecific background, and allowing the sample to incubate
  • An exemplary washing procedure includes washing with a solution such as PBS/Tween, PBS/Triton-X 100 or borate buffer.
  • the occurrence and amount of immunocomplex formation may then be determined by subjecting the bound immunocomplexes to a second antibody having specificity for the target that differs from the first antibody and detecting binding of the second antibody.
  • the second antibody will have an associated enzyme, e.g., urease, peroxidase or alkaline phosphatase, which will generate a color precipitate upon incubating with an appropriate chromogenic label.
  • a urease or peroxidase-conjugated anti-human IgG may be employed, for a period of time and under conditions which favor the development of immunocomplex formation (e.g., incubation for 2 hours at room temperature in a PBS -containing solution such as PBS/Tween).
  • the amount of label is quantified, for example by incubation with a chromogenic label such as urea and bromocresol purple in the case of a urease label or 2,2'- azino-di-(3-ethyl-benzthiazoline)-6-sulfonic acid (ABTS) and H 2 0 2 , in the case of a peroxidase label. Quantitation is then achieved by measuring the degree of color generation, e.g., using a visible spectrum spectrophotometer.
  • a chromogenic label such as urea and bromocresol purple in the case of a urease label or 2,2'- azino-di-(3-ethyl-benzthiazoline)-6-sulfonic acid (ABTS) and H 2 0 2 , in the case of a peroxidase label.
  • Quantitation is then achieved by measuring the degree of color generation, e.g., using a visible spectrum spectrophotometer
  • the data may be expressed in optical units, for example, as optical density or OD values if data are quantified using a visible spectrum
  • data may be expressed as absorbance, emission, radioactivity counts or the like depending on the reactive substrate used with the second antibody as described above.
  • the magnitude of optical units quantified from any well containing no detectable substrate for example a blank, may be subtracted from the optical units quantified from any well containing detectable substrate. This value may be an adjusted optical unit value, or an adjusted OD and included in further calculations described herein.
  • the magnitude of optical units quantified from any well containing no detectable substrate, for example a blank may not be subtracted from the optical units quantified from any well containing detectable substrate. This value may be a raw optical unit value or a raw OD and included in further calculations described herein.
  • non-ELISA based-methods for measuring the levels of one or more proteins in a sample may be employed.
  • Representative examples include but are not limited to mass spectrometry, chromatography, proteomic arrays, xMAPTM microsphere technology, flow cytometry, western blotting, spectroscopy, nephelometry, radial immunodiffusion techniques, single radial imn odiffusion assay, protein digestion and peptide analysis (e.g., the methods and systems described by Applied Proteomics) and immunohistochemistry.
  • Mass spectroscopy method may include any mass spectrometric (MS) techniques that can obtain precise information on the mass of peptides, and preferably also on fragmentation and/or (partial) amino acid sequence of selected peptides (e.g., in tandem mass spectrometry, MS/MS; or in post source decay, TOF MS), are useful herein.
  • MS/MS mass spectrometric
  • Suitable peptide MS and MS/MS techniques and systems are well-known per se and may be used herein, as well as liquid chromatography coupled to mass spectroscopy (LC-MS) and two-dimensional liquid chromatography coupled to tandem mass spectroscopy (2D-LC-MS/MS).
  • MS arrangements, instruments and systems suitable for biomarker peptide analysis may include, without limitation, matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) MS; MALDI-TOF post-source-decay (PSD); MALDI-TOF/TOF; surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF) MS; electrospray ionization mass spectrometry (ESI-MS); ESI-MS/MS; ESI-MS/(MS) n (n is an integer greater than zero); ESI 3D or linear (2D) ion trap MS; ESI triple quadrupole MS; ESI quadrupole orthogonal TOF (Q-TOF); ESI Fourier transform MS systems; desorption/ionization on silicon (DIOS); secondary ion mass spectrometry (SIMS); atmospheric pressure chemical ionization mass spectrometry (APCI-MS
  • MS/MS Peptide ion fragmentation in tandem MS
  • CID collision induced dissociation
  • Detection and quantification of biomarkers by mass spectrometry may involve multiple reaction monitoring (MRM).
  • MS peptide analysis methods may be advantageously combined with upstream peptide or protein separation or fractionation methods, such as for example with the chromatographic and other methods.
  • biomarker proteins can be derivatized or modified prior to analysis, measurement, quantification or the like. Methods known to those of ordinary skill in the art may be employed to derivatize or modify proteins. Polymorphisms or modifications to protein biomarkers listed herein may be identified using the methods described herein, using the analytical, measurement or quantification methods described herein.
  • the level of at least one PE biomarker may be evaluated by detecting in a patient sample the amount or level of one or more R A transcripts or a fragment thereof, encoded by the gene of interest to arrive at a nucleic acid marker representation.
  • the level of nucleic acids in the sample may be detected using any convenient protocol. While a variety of different manners of detecting nucleic acids are known, such as those employed in the field of differential gene expression analysis, one representative and convenient type of protocol for generating marker representations is array-based gene expression profiling protocols. Such applications are hybridization assays in which a nucleic acid that displays "probe" nucleic acids for each of the genes to be assayed/profiled in the marker representation to be generated is employed.
  • a sample of target nucleic acids is first prepared from the initial nucleic acid sample being assayed, where preparation may include labeling of the target nucleic acids with a label, e.g., a member of signal producing system.
  • a label e.g., a member of signal producing system.
  • the sample is contacted with the array under hybridization conditions, whereby complexes are formed between target nucleic acids that are
  • Specific hybridization technology which may be practiced to generate the marker representations employed in the subject methods includes the technology described in U.S. Patent Nos.: 5,143,854; 5,288,644; 5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980; 5,510,270; 5,525,464; 5,547,839; 5,580,732; 5,661,028; 5,800,992; the disclosures of which are herein incorporated by reference; as well as WO 95/21265; WO 96/31622; WO 97/10365; WO 97/27317; EP 373 203; and EP 785 280.
  • Arrays of "probe" nucleic acids that include a probe for each of the phenotype determinative genes whose expression is being assayed can be contacted with target nucleic acids from a subject sample. Contact is carried out under hybridization conditions, e.g., stringent hybridization conditions, and unbound nucleic acid is then removed.
  • hybridization conditions e.g., stringent hybridization conditions
  • unbound nucleic acid is then removed.
  • stringent assay conditions refers to conditions that are compatible to produce binding pairs of nucleic acids, e.g., surface bound and solution phase nucleic acids, of sufficient complementarity to provide for the desired level of specificity in the assay while being less compatible to the formation of binding pairs between binding members of insufficient complementarity to provide for the desired specificity.
  • Stringent assay conditions are the summation or combination (totality) of both hybridization and wash conditions.
  • the resultant pattern of hybridized nucleic acid provides information regarding expression for each of the genes that have been probed, where the expression information is in terms of whether or not the gene is expressed and, typically, at what level, where the expression data, e.g.,, marker representation (e.g., in the form of a transcriptosome), may be both qualitative and quantitative.
  • non-array based methods for quantitating the level of one or more nucleic acids in a sample may be employed, including those based on amplification protocols, e.g., Polymerase Chain Reaction (PCR)-based assays, including quantitative PCR, reverse- transcription PCR (RT-PCR), real-time PCR, loop mediated isothermal amplification of DNA (LAMP), strand displacement amplification (SDA), sequence based amplification (NASBA), self-sustained sequence replication (3SR), linear amplification, and the like.
  • PCR Polymerase Chain Reaction
  • functional assays, methods and protocols for determining the function of a protein hypothesized to be in a sample may be employed, including any standard functional assays known to one of ordinary skill in the art which would confirm or deny the presence of a hypothesized protein in a sample.
  • functional assay may include enzymatic assays, substrate assays, cleavage assays, colorimetric assays, pH assays and the like. Lysosome assays may also be performed.
  • the total amount protein or a portion of the total amount of protein in a sample may be
  • a colorimetric assay such as BCA, Lowry, Bradford, Coomassie, 660nm or the like.
  • a PE biomarker standard may be a purified recombinant protein, a purified protein, a synthetic protein, an engineered protein or the like that is similar to or the same as a biomarker measured by the methods described herein.
  • a biomarker standard is a purified recombinant protein that is similar to or the same as a biomarker measured by the methods described herein.
  • a blank may be water, a buffer, more than one buffer, a chemical, more than one chemical, a reagent, more than one reagent, an antibody, more than one antibody or any component of the methods described herein.
  • a low quality control may be a previously analyzed sample, be a purified recombinant protein, a purified protein, a synthetic protein, an engineered protein or the like which has a low level of the biomarker analyzed by the method described herein.
  • a high quality control may be a previously analyzed sample, be a purified recombinant protein, a purified protein, a synthetic protein, an engineered protein or the like which has a high level of the biomarker analyzed by the method described herein.
  • a curve standard may be a concentrated, diluted or purified protein supplied by the user or the manufacturer of an ELISA which may be used to analyze a level of total protein, or total biomarker levels, in order to calculate a standard curve for the method described herein, often an ELISA method.
  • the wells of a single plate may contain, but are not limited to, at least one sample, at least one biomarker standard, at least one curve standard, a high quality control, a low quality control and at least one blank. In some cases, the wells of a single plate may contain, but are not limited to, more than one sample, more than one biomarker standard, more than one curve standard, a high quality control, a low quality control and more than one blank.
  • the wells of a single plate may contain at least 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, or 10 samples; at least 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, or 10 biomarker standards; at least 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, or 10 curve standards; at least 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, or 10 high quality controls; at least 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, or 10 low quality controls; and/or at least 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, or 10 blanks.
  • the samples may be singles, duplicates, triplicates, quadruplicates, or any further extension of replicates.
  • a single ELISA assay plate contains eight standard curve samples in triplicate, six high quality control samples, six low quality control samples, and three samples in triplicate arrayed across the plate to avoid variation.
  • controls may be used in place of high quality control and/or low quality control.
  • controls may be used as an internal calibrator.
  • controls may be used in place of biomarker standards.
  • controls may be used in place of standards. For example, controls may be used to generate the standard curve described herein.
  • the disclosure further provides a method for confirming the presence, absence or severity of preeclampsia in a subject comprising: utilizing a monoclonal antibody that selectively binds fibronectin to determine the levels of fibronectin in a sample derived from the subject, generating a report indicating the presence, absence or severity of preeclampsia based on the levels and containing an index; and evaluating the sample and based upon the index, suggesting a treatment for preeclampsia, the treatment selected involving aspirin, preterm labor or bedrest.
  • a method of confirming, diagnosing, prognosing, monitoring, characterizing or evaluating the severity of preeclampsia in a subject comprises: deriving a biological sample from the subject; diluting the biotenylated hemopexin two fold, mixing the biotenylated hemopexin with the subject's biological sample, adding this mixture to an immunoassay plate; performing an analysis of the biological sample for the presence and amount of hemopexin (HPX) in an immunoassay test, and employing the biomarker level to provide a preeclampsia diagnosis, prognosis, confirmation, monitoring, characterization or evaluation of its severity.
  • the assay methodology exemplifies a competitive ELISA assay.
  • biotinylated hemopexin competes with the sample-hemopexin for antibody binding sites.
  • the amount of biotinylated hemopexin is subsequently detected spectroscopically following the introduction of appropriate conjugate forming partners such as avidin, strepavidin, NeutrAvidin®, human-derived biotin-binding molecules, and the like.
  • conjugate results in turn in a detectable signal.
  • ELISA kits may be used for performing ELISA assays. Those may be purchased from standard commercial manufacturers such as for example, disintegrin and
  • ADAM 12 Mybiosource
  • HPX hemopexin
  • MA Abeam Inc.
  • P1GF placental growth factor
  • MN R&D system Inc.
  • sFlt soluble fms- like tyrosine kinase
  • kits can include, but are not limited to, anti-PlGF (distributed by USCN Life Science Inc., Roche and R&D Systems), anti-sFlt-1 (distributed by Boster Bio., R&D systems, MyBioSource.com, antibodies-online, Biotrend Chemikalien GmbH, and Enzo Life Sciences), anti- PAPP-A (distributed by R&D systems, RayBioTech, IBL Japan, DRG International, Abnova, USCN Life Science, Novus Bio, Rapid Test, MyBioSource, antibodies-online.com, Fisher Scientific, elabscience, Sigma Aldrich, C USA Bio, ANSH Labs, Demeditec, Alpco, AMS Bio, NovaTeinBio, Creative Biomart, Biorbyt, Biomatic Corporation), anti-VEGF (distributed by VEGF (distributed by USCN Life Science Inc., Roche and R&D Systems), anti-sFlt-1 (distributed by Boster Bio., R&D systems, MyBioSource.com, antibodies-
  • Standard curve samples may be analyzed for concentration of biomarkers using the methods described herein, for example, using ELISA methods, protocols, assays and the like.
  • Each commercially available or in-house designed ELISA method, protocol and/or assay may provide instructions containing recommended dilutions of standard curve samples prior to performing the method, protocol and/or assay on a sample or a set of standard curve samples.
  • the instructions for the commercially available or in-house designed ELISA method, protocol and/or assay may be followed and standard curve samples diluted according to the instructions.
  • standard curve samples may be diluted to a ratio of 1 : 1 , 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:150, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1500, 1:2000, 1:2500, 1:3000, 1:3500, 1:4000, 1:10 000, 1:15000, 1:20000, 1:25000, 1:30000, 1:35000, 1:40000, 1:45000, 1:50000, 1:55 000, 1:60000, 1:65000, 1:70000, 1:75000, 1:80000, 1:85000, 1:90000, 1:
  • standard curve samples may be diluted to a ratio of about 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:150, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1500, 1:2000, 1:2500, 1:3000, 1:3500, 1:4000, 1:10000, 1:15000, 1:20000, 1:25000, 1:30000, 1:35 000, 1:40000, 1:45000, 1:50000, 1:55000, 1:60000, 1:65000, 1:70000, 1:75000, 1:80000, 1:85000, 1:90000, 1:95000 or 1:1
  • standard curve samples may be diluted to a ratio of less than 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:150, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1500, 1:2000, 1:2500, 1:3000, 1:3500, 1:4000, 1:10000, 1:15000, 1:20000, 1:25000, 1:30000, 1:35000, 1:40000, 1:45000, 1:50 000, 1:55000, 1:60000, 1:65000, 1:70000, 1:75000, 1:80000, 1:85000, 1:90000, 1:95000 or
  • standard curve samples may be diluted to a ratio of greater than 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:150, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1500, 1:2000, 1:2500, 1:3000, 1:3500, 1:4000, 1:10000, 1:15000, 1:20000, 1 :25 000, 1 :30 000, 1 :35 000, 1 :40 000, 1 :45 000, 1 :50 000, 1 :55 000, 1 :60 000, 1 :65 000, 1 :70 000, 1 :75 000, 1 :80 000,
  • the resultant data provides information regarding levels in the sample for each of the markers that have been probed, wherein the information is in terms of whether or not the marker is present and, typically, at what level, and wherein the data may be both qualitative and quantitative.
  • the methods provide a reading or evaluation, e.g., assessment, of whether or not the target marker, e.g., nucleic acid or protein, is present in the sample being assayed.
  • the methods provide a quantitative detection of whether the target marker is present in the sample being assayed, e.g., an evaluation or assessment of the actual amount or relative abundance of the target analyte, e.g., nucleic acid or protein in the sample being assayed.
  • the quantitative detection may be absolute or, if the method is a method of detecting plurality of different analytes, e.g., target nucleic acids or protein, in a sample, relative.
  • the measurement(s) may be analyzed in any of a number of ways to obtain a preeclampsia marker level representation.
  • a "biomarker level representation” or “gene representation” it is meant a representation of the levels, e.g.,. R A, DNA or protein levels, of one or more preeclampsia markers and/or protein cofactors of interest.
  • the preeclampsia marker measurements may be analyzed to produce a preeclampsia score or index which may be calculated using a logistic regression analysis.
  • a ratio of at least two biomarkers may be calculated and combined with additional explanatory variables for use in a model. Often the ratio of biomarkers may be the ratio of sFlt-1 and P1GF.
  • the model generated may be a penalized model. In other cases, the model generated may be an un-penalized model. A sample may contribute to an inaccurate model and as such, the out-of-sample performance may be evaluated to determine if a sample contributes to an inaccurate model.
  • the out-of-sample performance may be evaluated using any number of approaches, including but not limited to, a cross-validation approach.
  • the accuracy of the model depends on a number of parameters including, but not limited to, how representative the training sample is of the target population, the number of variables included in the model, biomarker measurement uncertainty, etc.
  • the out-of-sample performance of the model is often evaluated to estimate the error of the model in a sample set that has not been used for training.
  • the preeclampsia marker measurements may be analyzed as a biomarker panel.
  • Predictive members of the biomarker panel may be selected by statistical feature selection process.
  • the panel of analytes may be selected by combining genetic algorithm (GA) and all paired (AP) support vector machine (SVM) methods for preeclampsia classification analysis.
  • G genetic algorithm
  • AP all paired
  • SVM support vector machine
  • Predictive features are automatically determined, e.g. through iterative GA/SVM, leading to very compact sets of non-redundant preeclampsia- relevant analytes with the optimal classification performance. It is possible that these different classifier sets harbor only modest overlapping gene, protein fragment or protein features, but have similar levels of accuracy.
  • the preeclampsia marker measurements may be analyzed to generate a preeclampsia signature.
  • a preeclampsia signature for a patient sample may be calculated by any of a number of methods known in the art for calculating biomarker signatures.
  • the levels of each of the one or more preeclampsia markers in a patient sample may be log 2 , loge or logio transformed, and normalized, e.g., as described above for generating a preeclampsia marker profile.
  • the normalized expression levels for each marker is then weighted by multiplying the normalized level to a weighting factor, or weight, to arrive at weighted expression levels for each of the one or more markers.
  • the weighted levels are then totaled and in some cases averaged to arrive at a single weighted level for the one or more preeclampsia markers analyzed.
  • a PE test can confirm whether or not a subject suspected of having PE actually does have PE.
  • the single weighted level for the one or more preeclampsia markers analyzed can confirm the severity of PE.
  • the single weighted level can yield high, medium or low weighted scores which can confirm high, medium or low severity of PE in a subject.
  • a high single weighted level confirms a high severity of PE in a subject.
  • a medium single weighted level confirms a high severity of PE.
  • a low single weighted level confirms a high severity of PE.
  • a high single weighted level confirms a medium severity of PE.
  • a medium single weighted level confirms a medium severity of PE. In some instances, a low single weighted level confirms a medium severity of PE. In some instances, a high single weighted level confirms a low severity of PE. In some instances, a medium single weighted level confirms a low severity of PE. In some instances, a low single weighted level confirms a low severity of PE in a subject.
  • the single weighted level for the one or more preeclampsia markers analyzed can indicate the likelihood that a subject suspected of having PE has or doesn't have PE.
  • the single weighted level can yield high, medium, and low weighted scores which can indicate the likelihood of a subject having or not having PE.
  • a high single weighted level indicates a high likelihood of a subject having or not having PE.
  • a medium single weighted level indicates a high likelihood of a subject having or not having PE.
  • a low single weighted level indicates a high likelihood of a subject having or not having PE.
  • a high single weighted level indicates a medium likelihood of a subject having or not having PE.
  • a medium single weighted level indicates a medium likelihood of a subject having or not having of PE. In some instances, a low single weighted level indicates a medium likelihood of a subject having or not having PE. In some instances, a high single weighted level indicates a low likelihood of a subject having or not having PE. In some instances, a medium single weighted level indicates a low likelihood of a subject having or not having PE. In some instances, a low single weighted level indicates a low likelihood of a subject having or not having PE.
  • the single weighted level for the one or more preeclampsia markers analyzed can indicate the likelihood that a subject will develop preeclampsia.
  • the single weighted level can yield high, medium, and low weighted scores which can indicate the likelihood that a subject will develop preeclampsia prior to having any symptoms.
  • a high single weighted level indicates a high likelihood that a subject will develop preeclampsia.
  • a medium single weighted level indicates a high likelihood that a subject will develop preeclampsia.
  • a low single weighted level indicates a high likelihood that a subject will develop preeclampsia.
  • a high single weighted level indicates a medium likelihood that a subject will develop preeclampsia. In some instances, a medium single weighted level indicates a medium likelihood that a subject will develop preeclampsia. In some instances, a low single weighted level indicates a medium likelihood that a subject will develop preeclampsia. In some instances, a high single weighted level indicates a low likelihood that a subject will develop preeclampsia. In some instances, a medium single weighted level indicates a low likelihood that a subject will develop preeclampsia. In some instances, a low single weighted level indicates a low likelihood that a subject will develop preeclampsia.
  • the weighting factor, or weight may be determined by any statistical machine learning methodology, for example, Principle Component Analysis (PCA), linear regression, support vector machines (SVMs), and/or random forests of the dataset from which the sample was obtained may be used.
  • PCA Principle Component Analysis
  • SVMs support vector machines
  • the analyte level of each preeclampsia marker may be log 2 , loge or logio transformed and weighted either as 1 (for those markers that are increased in level in preeclampsia) or -1 (for those markers that are decreased in level in preeclampsia), and the ratio between the sum of increased markers as compared to decreased markers determined to arrive at a preeclampsia signature.
  • a preeclampsia signature is an example of a preeclampsia marker level representation.
  • the relative weight of plurality of markers is used to determine a biomarker signature, biomarker score or biomarker index.
  • Markers whose weight may be compared include any of the markers described herein or those selected from a group comprising HPX, sFlt-1, PAPP-A, FN, FG, VEGF (excluding VEGF-R1), P1GF and
  • a PE signature, PE score or PE index involves comparing the levels of sFlt-1 and P1GF in combination with at least one other biomarker and determining if their relative weight is at least 1.5: 1, 2: 1, 2.5: 1, 3: 1 or 3.5: 1 respectively, wherein such a determination is indicative of PE or likelihood of PE.
  • the PE score or PE index can be further categorized into values that confirms the severity of PE in a subject.
  • the PE score or PE index can yield high, medium or low values which can confirms the severity of PE in a subject.
  • a high PE score or PE index can confirms a high severity of PE in a subject.
  • a medium PE score or PE index confirms a high severity of PE.
  • a low PE score or PE index confirms a high severity of PE.
  • a high PE score or PE index confirms a medium severity of PE.
  • a medium PE score or PE index confirms a medium severity of PE.
  • a low PE score or PE index confirms a medium severity of PE.
  • a high PE score or PE index confirms a low severity of PE. In some instances, a medium PE score or PE index confirms a low severity of PE. In some instances, a low PE score or PE index confirms a low severity of PE in a subject.
  • the PE score or PE index can be further categorized into values that indicate the likelihood that a subject suspected of having PE has or does not have PE.
  • PE score or PE index can yield high, medium, and low values which can indicate the likelihood of a subject having or not having PE.
  • a high PE score or PE index indicates a high likelihood of a subject having or not having PE.
  • a medium PE score or PE index indicates a high likelihood of a subject having or not having PE.
  • a low PE score or PE index indicates a high likelihood of a subject having or not having PE.
  • a high PE score or PE index indicates a medium likelihood of a subject having or not having PE.
  • a medium PE score or PE index indicates a medium likelihood of a subject having or not having of PE.
  • a low PE score or PE index indicates a medium likelihood of a subject having or not having PE.
  • a high PE score or PE index indicates a low likelihood of a subject having or not having PE.
  • a medium PE score or PE index indicates a low likelihood of a subject having or not having PE.
  • a low PE score or PE index indicates a low likelihood of a subject having or not having PE.
  • the PE score or PE index can be further categorized into values that can predict the likelihood that a subject will develop preeclampsia prior to the onset of symptoms (e.g., high, medium or low likelihood).
  • a high PE score or PE index indicates a high likelihood that a subject will develop preeclampsia.
  • a medium PE score or PE index indicates a high likelihood that a subject will develop preeclampsia.
  • a low PE score or PE index indicates a high likelihood that a subject will develop preeclampsia.
  • a high PE score or PE index indicates a medium likelihood that a subject will develop preeclampsia.
  • a medium PE score or PE index indicates a medium likelihood that a subject will develop preeclampsia. In some instances, a low PE score or PE index indicates a medium likelihood that a subject will develop preeclampsia. In some instances, a high PE score or PE index indicates a low likelihood that a subject will develop preeclampsia. In some instances, a medium PE score or PE index indicates a low likelihood that a subject will develop preeclampsia. In some instances, a low PE score or PE index indicates a low likelihood that a subject will develop preeclampsia.
  • the data may be processed and/or further analyzed using any number of methods, algorithms and calculations in order to prioritize the individual data points, data sets and prevent over-fitting of false positive or falsely correlated results.
  • some data may not be corrected, for example training data, which may be at times an optimistic estimate of the data.
  • some data may be corrected, for example, corrected data, which may be at times a conservative estimate of the data.
  • the corrected data are a cross-validated estimate of a value, for example the value may be the area under the curve (AUC).
  • the performance of the model is evaluated on the training data providing an optimistic estimate. Occasionally, a correction for optimism estimate of performance is calculated for different performance metrics.
  • the corrected performance estimate is calculated using cross-validation.
  • the performance metric is the area under the curve (AUC) or ROC value.
  • Data may be used to prepare models.
  • the models are penalized or optimized. Models derived from using penalized data treat biomarkers individually and prevents the data acquired for each individual biomarker, or replicate data measurement for each biomarker, from controlling the preeclampsia index, preeclampsia score or preeclampsia profile.
  • the data used in penalized models controls the preeclampsia index, preeclampsia score or preeclampsia profile by improperly weighting the preeclampsia index, preeclampsia score or preeclampsia profile to one direction or another.
  • the data is used in a penalized model such that the preeclampsia index, preeclampsia score or preeclampsia profile is not improperly weighted and prevents the preeclampsia index, preeclampsia score or preeclampsia profile from being determined on an unrelated factor, such as a damaged sample, a sample not reflective of the subject, etc.
  • optimized models are derived from data such that correction may prevent the acquired data value for an individual marker from falsely contributing to the equation.
  • corrected and/or optimized models are derived from data that may be more predictive of a preeclampsia index, preeclampsia score or preeclampsia profile compared to the training numbers.
  • a model is constructed using a penalized logistic regression approach, wherein the penalized approach fits a regression model while adding a constraint on the sum of the absolute values of the coefficients of the model described herein. The constraint may prevent variables that might be highly associated with the outcome in this sample set from falsely affecting the model.
  • preeclampsia score or preeclampsia profile includes the ratio of sFlt-1 and P1GF. This ratio may or may not be normalized along with the assay result.
  • the preeclampsia index, preeclampsia score or preeclampsia profile is a combination of biomarkers that may be determined using the analysis methods described herein.
  • Tier I corresponds to ROC values of at least 0.98 or more.
  • Tier II corresponds to ROC values between 0.92 and 0.98, and Tier III corresponds to ROC values of 0.92 or less.
  • ROC values greater than 0.850 may be clinically valuable.
  • ROC values greater than 0.90 or 0.950 may be clinically valuable.
  • the tier values may be ROC values which may indicate the sensitivity and/or specificity of a method and or a data point for a particular biomarker or set of biomarkers.
  • the data outputs may be classified using at least one algorithm, at least one threshold value, at least directional change over time, comparisons within a single subject, comparisons within a group of subjects or comparisons to a reference standard.
  • the at least one algorithm may be an algorithm described herein or at least one known to one of ordinary skill in the art.
  • the at least one threshold value may be described herein or known to one of ordinary skill in the art.
  • the threshold value may be set based on a single parameter or a set of parameters; either the single or the set may be defined by the user.
  • the directional change may be described herein or known to one of ordinary skill in the art.
  • the directional change may be based on a single parameter or a set of parameters; either the single or the set may be defined by the user.
  • the comparisons within a single subject may be described herein or known to one of ordinary skill in the art.
  • the comparisons within a single subject (which may be the same or different from the tested subject) may be based on a single parameter or a set of parameters; either the single or the set may be defined by the user.
  • the comparisons within a group of subjects may be described herein or known to one of ordinary skill in the art.
  • the comparisons within a group of subjects may be based on a single parameter or a set of parameters; either the single or the set may be defined by the user.
  • comparisons to a reference standard may be described herein or known to one of ordinary skill in the art.
  • the comparisons to a reference standard may be based on a single parameter or a set of parameters; either the single or the set may be defined by the user.
  • the reference standard may be based on actual test subject or subjects, or other experimental values, or a theoretical value derived from a model, or on any combination thereof.
  • the disclosure provides for a method for confirming the presence or the absence of preeclampsia in a subject comprising: evaluating a plurality of biomarkers in a sample derived from the subject to confirm if the subject has or does not have preeclampsia wherein the confirmation has a specificity of at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or more, which is used to calculate an index.
  • the confirmation has an AUC of at least 0.9, 0.91, 0.92, 0.93, 0.95, 0.96, 0.97, 0.980, 0.985, 0.988, 0.990, 0.995, 0.999 or more, which is used to calculate an index.
  • a sample derived from more than subject is evaluated to confirm the presence or the absence of PE, at a specificity described herein, for examples samples from more than 5, 10, 50, 100, 130, 135, 138, 150, 200, 220, 247, 250, 300, 350, 400, 450, 500, or more than 1000 subjects are evaluated to confirm the presence or the absence of PE at a specificity described herein.
  • the subject is evaluated as having PE using traditional methods.
  • the subject actually experiences PE.
  • Traditional methods involve measuring proteinuria, blood pressure, weight gain, blood glucose, platelet count and any other method traditionally used to evaluate PE known in the art.
  • the disclosure further provides a method for distinguishing a subject having preeclampsia from a subject having symptoms suggestive of preeclampsia but who does not have preeclampsia, the method distinguishing preeclampsia from complication of pregnancy symptoms, chronic hypertension, gestational hypertension, autoimmune disorders and/or gestational diabetes, wherein the method has a specificity of at least 95%, or has an AUC of at least 0.9, comprising: evaluating the level of a plurality of different biomarkers from a sample derived from the subject, generating an index indicative of the presence of preeclampsia, absence of preeclampsia, severity of preeclampsia.
  • the method further comprises based upon the index, suggesting a treatment for preeclampsia, the treatment involving aspirin, preterm labor or bedrest.
  • the autoimmune disorder is SLE or lupus.
  • the method further comprises weighting each of the plurality of biomarkers, wherein the weighting includes providing numbers into a polynomial such that each marker has a distinct weight.
  • the disclosure provides a method for confirming the presence or the absence of preeclampsia in a subject comprising: evaluating a plurality of biomarkers in a sample derived from the subject to confirm if the subject has preeclampsia wherein the confirmation has a specificity of greater than 95%, or has an AUC greater than 0.9 and is used to calculate an index.
  • the disclosure further provides a method for diagnosing or confirming a presence of preeclampsia in a subject comprising: (a) performing at least two different assays that determine a level of fibronectin in a sample derived from the subject; and (b) evaluating the sample and using the levels from the two different assays to diagnose or confirm the presence of preeclampsia and calculate an index.
  • the disclosure provides a method for diagnosing or confirming a presence of preeclampsia in a subject comprising: (a) performing at least one assay which utilizes an antibody which binds fibronectin or an antibody that selectively binds a same antigen of fibronectin as the antibody, wherein the binding of the antibody determines a level of fibronectin in a sample derived from the subject; and (b) evaluating the sample and using the level of fibronectin from the at least one assay to diagnose or confirm the presence of preeclampsia and calculating an index.
  • the disclosure also describes a method for diagnosing or confirming a presence of preeclampsia or the absence of preeclampsia in a subject comprising: (a) evaluating a level of a ratio of sFlt-1 and P1GF and a level a plurality of different biomarkers in a sample derived from the subject, wherein the different biomarker is not ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotem E (ApoE), apolipoprotem C-III (Apo-C3), apolipoprotem A-1 (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM), free human chorionic gonadotropin (free beta hCG) or heme
  • the disclosure further provides a method for distinguishing a subject having preeclampsia from a subject having symptoms suggestive of preeclampsia but who does not have preeclampsia, the method distinguishing preeclampsisa from complication of pregnancy symptoms, chronic hypertension, gestational hypertension, autoimmune disorders and/or gestational diabetes, wherein the method has a specificity of at least 90% or AUC of at least 0.9 comprising: evaluating the level of a plurality of different biomarkers from a sample derived from the subject, generating an index indicative of the presence of PE, absence of PE, characteristics of PE, severity of PE, diagnosis of PE or prognosis of PE.
  • the disclosure further describes a method for analyzing the diagnosis, prognosis, characteristics, presence, absence or severity of preeclampsia in a subject comprising: (a) utilizing a monoclonal antibody that selectively binds fibronectin to determine the levels of fibronectin in a sample derived from the subject, (b) generating a report indicating the presence, absence or severity of preeclampsia based on the levels and containing an index; and (c) evaluating the sample and based upon the index, suggesting a treatment for preeclampsia, the treatment involving aspirin, preterm labor or bedrest.
  • the disclosure also describes a method for analyzing the diagnosis, prognosis, characteristics, presence, absence or severity of preeclampsia in a sample derived from a subject comprising: utilizing an antibody directed to the antigen of the fibronectin antibody in at least one fibronectin ELISA kit to analyze and evaluate a sample from the subject.
  • the disclosure further provides a method for diagnosing or confirming a presence of preeclampsia in a subject comprising: (a) performing at least one assay which utilizes an antibody that selectively binds fibronectin, a portion of fibronectin, a part of fibronectin or a fragment of fibronectin, wherein the binding of the antibody determines the level of fibronectin in a sample derived from the subject; and (b) evaluating the sample and using the level of fibronectin from the one assay to diagnose or confirm the existence of preeclampsia and calculate an index.
  • the disclosure describes a method for confirming that a subject does not have preeclampsia comprising: evaluating a plurality of biomarkers in a sample derived from the subject to confirm the subject does not have preeclampsia wherein the confirmation has a specificity of greater than 95% or has an 0.9 AUC and is used to calculate an index.
  • a PE signature, PE score or PE index involves comparing the levels of FN, FG, and another biomarkers selected from the following: HPX, sFlt- 1 , PAPP-A, VEGF (excluding VEGF-R1), P1GF and ADAM 12; and determining if their relative weight is at least 3: 1, 5: 1, 10: 1, 20: 1, 30: 1, 50: 1, 50:1, 100: 1, respectively, wherein such a determination is indicative of PE or likelihood of PE.
  • Other combinations of interest include comparing sFlt-1 and another biomarkers selected from the following: HPX, FN, FG, PAPP-A, VEGF (excluding VEGF-R1), P1GF and ADAM 12 and determining if their relative weight is at least 2: 1, 2.5: 1 3: 1, 5: 1, 10: 1, 20: 1, 30: 1, 50: 1, 50: 1, 100:1, respectively, wherein such a determination is indicative of PE or likelihood of PE.
  • P1GF comparing P1GF and another biomarkers selected from the following: HPX, sFlt-1, PAPP-A, VEGF (excluding VEGF-R1), FN, FG, and ADAM 12 and determining if their relative weight is at least 2: 1, 2.5: 1 3: 1, 5: 1, 10: 1, 20: 1, 30: 1, 50: 1, 50: 1, 100:1, respectively, wherein such a determination is indicative of PE or likelihood of PE.
  • biomarkers selected from the following: HPX, sFlt-1, PAPP-A, VEGF (excluding VEGF-R1), FN, FG, and ADAM 12 and determining if their relative weight is at least 2: 1, 2.5: 1 3: 1, 5: 1, 10: 1, 20: 1, 30: 1, 50: 1, 50: 1, 100:1, respectively, wherein such a determination is indicative of PE or likelihood of PE.
  • VEGF excluding VEGF-R1
  • another biomarkers selected from the following: HPX, sFlt-1, PAPP-A, P1GF, FN, FG, and ADAM12; and determining if their relative weight is at least 2: 1, 2.5: 1 3:1, 5: 1, 10: 1, 20: 1, 30: 1, 50: 1, 50: 1, 100: 1, respectively, wherein such a determination is indicative of PE or likelihood of PE.
  • the preeclampsia marker measurements may be analyzed to produce a preeclampsia score.
  • a preeclampsia score is a single metric value that represents the sum of the weighted levels of one or more preeclampsia markers in a patient sample.
  • a preeclampsia score may be determined by methods very similar to those described above for a preeclampsia signature, e.g.
  • the levels of each of the one or more preeclampsia markers in a patient sample may be log 2 , log e or logio transformed and normalized, e.g., as described above for generating a preeclampsia profile; the normalized expression levels for each marker is then weighted by multiplying the normalized level to a weighting factor, or weight, to arrive at weighted levels for each of the one or more markers; and the weighted levels are then totaled and in some cases averaged to arrive at a single weighted level for the one or more preeclampsia markers analyzed.
  • the weighted levels for the one or more preeclampsia markers may be subsequently transformed, for example using a logarithm-like inverse functions such as double logarithm ln(ln(x)), super-4-logarithm (i.e. tetra logarithm), hyper-4-logarithm (i.e. tetration), iterated logarithm, Lambert W function, or logit.
  • a logarithm-like inverse functions such as double logarithm ln(ln(x)), super-4-logarithm (i.e. tetra logarithm), hyper-4-logarithm (i.e. tetration), iterated logarithm, Lambert W function, or logit.
  • the weighted levels are defined by a reference dataset, or training dataset.
  • the preeclampsia score is defined by a reference dataset.
  • a preeclampsia index is an example of a preeclampsia marker level representation.
  • a PE index is a metric system that indicates severity of PE or the degree of likelihood of developing PE. It is used to determine in what class the female subject is in.
  • the PE index is calculated from the PE score, using a classification algorithm. Examples for classification algorithms are well known in the art. These algorithms can be formed using any suitable statistical classification (or "learning") method that attempts to segregate bodies of data into classes based on objective parameters present in the data. Classification methods may be either supervised or unsupervised. Examples of supervised and unsupervised classification processes are described in Jain, "Statistical Pattern Recognition: A Review," IEEE Transactions on Pattern Analysis and Machine Intelligence, Vol. 22, No. 1, January 2000.
  • supervised classification training data containing examples of known categories are presented to a learning mechanism, which learns one or more sets of relationships that define each of the known classes. New data may then be applied to the learning mechanism, which then classifies the new data using the learned relationships.
  • supervised classification processes include linear regression processes (e.g., multiple linear regression (MLR), partial least squares (PLS) regression and principal components regression (PCR)), binary decision trees (e.g., recursive partitioning processes such as CART-classification and regression trees), artificial neural networks such as back propagation networks, discriminant analyses (e.g., Bayesian classifier or Fischer analysis), logistic classifiers, and support vector classifiers (support vector machines).
  • MLR multiple linear regression
  • PLS partial least squares
  • PCR principal components regression
  • binary decision trees e.g., recursive partitioning processes such as CART-classification and regression trees
  • artificial neural networks such as back propagation networks
  • discriminant analyses e.g., Bayesian classifier or Fischer analysis
  • Recursive partitioning processes use recursive partitioning trees to classify spectra derived from unknown samples. Further details about recursive partitioning processes are provided in U.S. Patent Application No. 2002/0138208 Al to Paulse et al, "Method for Analyzing Mass Spectra.”
  • preeclampsia index described herein is not based on at least one of the factors in the group comprising blood pressure, weight gain, water retention, hereditary factors, proteinurea, headache, edema, protein/creatinine ratio, platelet count, stress, PE in prior pregnancies, nulliparity, age, age less than 20 years, age greater than 35, race, African-American and
  • the classification of PE that is used to provide the preeclampsia index described herein is not based on any of the characteristics just delineated in this paragraph.
  • the classification of PE that is used to provide the preeclampsia index described herein is based on at least one of the factors in the group comprising blood pressure, weight gain, water retention, hereditary factors, proteinurea, headache, edema, protein/creatinine ratio, platelet count, stress, PE in prior pregnancies, nulliparity, age, age less than 20 years, age greater than 35, race, African-American and NHL decent, serotype, Papanicolaou test results (Pap smear), prior preeclampsia episodes, familial history, number of pregnancies, number of miscarriages, body mass index (BMI), gestational diabetes, type I diabetes, obesity, glucose level, current and past medications, stress, PE in prior pregnancies (of the subject or her family members), chronic hypertension, renal disease and
  • the expression (e.g., polypeptide level) of only one marker is evaluated to produce a marker level representation.
  • the expression of plurality of markers e.g., at least 1, 2, 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 15, or more markers. Accordingly, in the subject methods, the expression of at least one marker in a sample is evaluated. In certain cases, the evaluation that is made may be viewed as an evaluation of the proteome, as that term is employed in the art.
  • the marker level representation arrived at in this manner finds many uses in diagnosing, prognosing, characterizing, evaluating the severity of preeclampsia, or in confirming the presence or the absence of preeclampsia.
  • the marker level representation may be employed to predict if a subject will develop preeclampsia, to diagnose preeclampsia in a subject, to characterize a diagnosed preeclampsia, or to monitor the responsiveness of the subject to treatment for preeclampsia.
  • the measurement of particular combinations of preeclampsia markers disclosed herein provides for a preeclampsia prognosis that has an improved accuracy over a preeclampsia prognosis made using standard methods known in the art, e.g. VEGF-R1 (e.g., sFLT-1) and P1GF.
  • VEGF-R1 e.g., sFLT-1
  • P1GF e.g., sFLT-1
  • the marker level representation may be employed in a method for diagnosing, prognosing, monitoring, characterizing or evaluating the severity of
  • Such method comprises: deriving a biological sample from a subject; performing an analysis of the subject's biological sample for the presence and amount of P1GF , HPX, sFlt-1 (i.e.
  • VEGF-R1 VEGF-R1
  • PAPP-A VEGF (excluding VEGF-R1)
  • VEGF excluding VEGF-R1
  • FN FN
  • FG FG
  • ADAM 12 employing the biomarker level to provide a preeclampsia diagnosis or prognosis
  • the weight comprises: generating a biomarker profile, and determining a single weighted level of the biomarker; wherein the profile comprises expression log 2 , log e or logio transformation and normalization; wherein weight level comprises multiplying the profile with a weighting factor, and wherein the weighting factor is calculated by a method comprising statistical machine learning method which may include, for example, any of the following: Principle Component Analysis (PC A), linear regression, support vector machines (SVMs), and random forests analysis.
  • PC A Principle Component Analysis
  • SVMs support vector machines
  • the marker level representation may be employed in a method diagnosing, prognosing, monitoring, characterizing, evaluating the severity of preeclampsia, or confirming the presence or the absence of preeclampsia in a subject based on relative weights of biomarkers.
  • Such method comprises: deriving a biological sample from the subject; performing an analysis of her biological sample for the presence and amount P1GF, HPX, sFlt- 1 , PAPP-A, VEGF (excluding VEGF-R1 ), and ADAM 12; employing the biomarker level to provide a preeclampsia diagnosis or prognosis; wherein the relative level of FN, FG, to the number of biomarkers is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50 or more.
  • the disclosure provides a method for confirming if a subject does not have preeclampsia comprising: evaluating a sample derived from the subject to determine level of plurality of biomarkers in the sample, using the levels of the plurality of biomarkers to calculate an index representative of a likelihood that the subject does not have preeclampsia; and based upon the index, confirming if the subject does not have preeclampsia.
  • the evaluating does not comprise comparing a sample derived from the subject at a first time point and a sample derived from the same subject at a second time point.
  • the evaluating does comprise comparing a sample derived from the subject at a first time point and a sample derived from the same subject at a second time point.
  • the method further comprises, based upon the index, suggesting a treatment for preeclampsia, the treatment involving aspirin, preterm labor or bedrest.
  • the plurality of biomarkers are selected from the group comprising sFlt-l,PlGF, FN and PAPP- A; sFlt-1, PIGF, FN, ADAM 12 and PAPP-A; sFlt-1, PIGF, PAPP-A and FN; sFlt-1, PIGF, HPX, FN and PAPP-A; PIGF, ADAM 12, FN and PAPP-A; PIGF, FN and PAPP-A; sFlt-1, PIGF and FN; PIGF, FN and PAPP-A; sFlt-1, PIGF, FN and ADAM 12; sFlt-1, PIGF and FN; PIGF, sFlt-1 and FN; sFlt-1, FN and ADAM 12; or PIGF, FN and PAPP-A.
  • the calculating further comprises determining a ratio of levels of sFlt-1 and PIGF.
  • the marker level representation is employed by comparing it to a phenotype determination element, e.g., a preeclampsia phenotype determination element, to identify similarities or differences with the phenotype determination element, where the similarities or differences that are identified are then employed to predict if a subject will develop preeclampsia, to diagnose preeclampsia in a subject , to characterize a diagnosed preeclampsia, to monitor the responsiveness of the subject to treatment for preeclampsia, to evaluate the severity of preeclampsia, etc.
  • a phenotype determination element e.g., a preeclampsia phenotype determination element
  • a preeclampsia phenotype determination element may be a sample derived from an individual that has or does not have preeclampsia. Such sample may be used, for example, as a reference or control in the experimental determination of the marker representation for a given subject.
  • a preeclampsia phenotype determination element may be a marker level representation (e.g., marker profile, signature, score or index) that is representative of a preeclampsia state and may be used as a reference or control to interpret the marker level representation of a given subject.
  • the phenotype determination element may be a positive reference or control.
  • the positive reference or control may be a sample or marker level representation thereof from a subject that has preeclampsia, or that will develop preeclampsia, or that has preeclampsia that is manageable by known treatments, or that has preeclampsia that has been determined to be responsive only to the delivery of the baby.
  • the phenotype determination element may be a negative reference or control.
  • the negative reference or control may be a sample or marker level representation thereof from a subject that has not developed preeclampsia, or a subject that is not pregnant.
  • the marker representations are obtained from the same type of sample as the sample that was employed to generate the marker representation for the individual being monitored.
  • the phenotype determination elements are obtained from the same type of sample. For example, if the serum of an individual is being evaluated, the reference or control would preferably be of serum.
  • the obtained marker level representation is compared to a single phenotype determination element to obtain information regarding the individual being tested for preeclampsia.
  • the obtained marker level representation is compared to plurality of phenotype determination elements.
  • the obtained marker level representation may be compared to a negative reference and a positive reference to obtain confirmed information regarding if the individual will develop preeclampsia.
  • the obtained marker level representation may be compared to a reference that is representative of a preeclampsia which is responsive to treatment, and a reference that is representative of a preeclampsia that is not responsive to treatment, in order to obtain information as to whether or not the patient will be responsive to treatment.
  • the comparison of the obtained marker level representation and the one or more phenotype determination elements may be performed using any convenient methodology known to those of skill in the art.
  • array profiles may be compared by, e.g., comparing digital images of the expression profiles, by comparing databases of expression data, etc.
  • Patents describing ways of comparing expression profiles include, but are not limited to, U.S. Patent Nos. 6,308,170 and 6,228,575, the disclosures of which are herein incorporated by reference. Methods of comparing marker level profiles are also described above.
  • ELISAs will know that ELISA data may be compared by, e.g.
  • the comparison step results in information regarding how similar or dissimilar the obtained marker level profile is to the control or reference profile(s), and which similarity or dissimilarity information is employed to diagnose, prognose, monitor, characterize or evaluate the severity of preeclampsia, or confirm the presence or absence of preeclampsia in order to predict the onset of a
  • preeclampsia diagnose preeclampsia, monitor a preeclampsia patient, evaluate the severity of PE, characterize PE, confirm the presence of PE or confirm the absence of PE. Similarity may be based on relative marker levels, absolute marker levels or a combination of both.
  • a similarity determination is made using a computer having a program stored thereon that is designed to receive input for a marker level result obtained from a subject, e.g., from a user, determine similarity to one or more reference profile, and return a preeclampsia prognosis, e.g., to a user (e.g., lab technician, physician, lay person, pregnant female, etc.). Further descriptions of computer-implemented cases of the disclosure are described below.
  • the above comparison step yields a variety of different types of information regarding the cell or bodily fluid that is assayed. As such, the above comparison step can yield a positive or negative prediction of the onset of
  • Such a comparison step can yield a positive or negative diagnosis of preeclampsia.
  • such a comparison step can provide a
  • the PE marker level representation may be based on a threshold value.
  • the method may also involve obtaining levels of one or more biomarkers and comparing the levels to a pre-determined threshold (e.g. a standard value). Such threshold may be determined according to the concentration of a biomarker.
  • the threshold for prediction and/or confirmation of PE may be determined according to the relative concentration of a biomarker in a subject tested for PE or having PE as compared to a control (e.g., the same subject pre-pregnancy or at an earlier stage in pregnancy or another female in the same or another gestation period without PE).
  • an indication of PE or likelihood of PE, or severity of PE may be a FN, concentration that is increased by a factor of at least, 100, at least 500, at least 1 ,000, at least 2,000, at least 3,000, at least 4,000, at least 5,000, at least 10,000, at least 12,000, at least 15,000, at least 20,000, at least 30,000, at least 40,000, at least 50,000, at least 100,000 or at least 20,000 relative to control; and/or VEGF concentration increased a factor of at least 2, at least 4, at least, at least 8, at least 10, at least 15, at least 20, at least 30, at least 40 or at least 50 relative to control; and/or concentration decreased by a factor of at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 1 10, at least 120, at least 130, at least 140 or at least 150 relative to a control; and/or Fms-like tyrosine kinase 1 (sFltl)
  • ADAM 12 concentration increased by a factor of at least 2, at least 5, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 relative to control.
  • no physical characteristics aside from biomarker level is taken into account when diagnosing, prognosing, monitoring, characterizing or evaluating the severity of preeclampsia, or when confirming the presence or absence of PE in a subject.
  • gestation period is taken into account when confirming, diagnosing, prognosing, monitoring, characterizing or evaluating the severity of preeclampsia.
  • gestational period may be divided into early and late gestational period.
  • other elements may be taken to account comprising the subject's blood pressure, familial history and urine protein index.
  • Such analyses are well known in the art, and take into account, for example, blood pressure, weight gain, water retention, hereditary factors, proteinurea, headache, edema, protein/creatinine ratio, platelet count, stress, PE in prior pregnancies (of the subject or her family members), nulliparity, age, age less than 20 years, age greater than 35, race, African- American and Filipino decent, serotype, Papanicolaou test results (Pap smear), prior preeclampsia episodes, familial history, number of pregnancies, number of miscarriages, body mass index (BMI), gestational diabetes, type I diabetes, obesity, glucose level, current and past medications, chronic hypertension, renal disease, thrombophilia well as other characteristics of the pregnancy.
  • BMI body mass index
  • a test for PE measuring biomarkers from a subject's biological sample may provide predictive performance of each biomarker panel analysis, as evaluated by ROC curve analysis (Zweig et al. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clinical chemistry 1993;39:561-77; Sing et al. ROCR: visualizing classifier performance in R. Bioinformatics 2005;21 :3940-1).
  • the PE signature, score or index may have a cumulative ROC value of at least 0.8, 0.85, 0.9, 0.95, 0.96, 0.97, 0.980, 0.985, 0.988, 0.990, 0.995, 0.998 or more.
  • the PE signature, score or index may have a cumulative ROC value of at most 0.9, 0.95, 0.96, 0.97, 0.980, 0.985, 0.988, 0.990, 0.995, 0.998 or less.
  • the PE threshold, signature, score or index can have a sensitivity of at least 60%, 65%>, 70%>, 75%>, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; and/or a specificity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
  • the PE threshold, signature, score or index can have a sensitivity of at most 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; and/or a specificity of at most 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
  • Such PE signature, score or index can be for prognosis, diagnosis, monitoring, characterization or evaluating the severity of PE, confirming the absence of PE, or confirming the presence of PE, early PE, or late PE.
  • Such PE signature, score or index preferably comprises up to 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 biomarkers. ROC values may be applicable to biomarker signature, score, threshold or index.
  • the prediction, diagnosis, prognosis, monitoring, characterization, evaluating the severity of PE, or confirming the presence or absence of PE may be provided by providing, e.g., generating, a written report that includes the artisan's monitoring assessment, e.g., the artisan's prediction of the onset of preeclampsia (a "preeclampsia prediction"), the artisan's diagnosis of preeclampsia (a "preeclampsia diagnosis”), the artisan's confirmation of the presence of preeclampsia (a "preeclampsia positive
  • preeclampsia negative confirmation the artisan's confirmation of the absence of preeclampsia
  • a subject method may further include a step of generating or outputting a report providing the results of an assessment, which report can be provided in the form of an electronic medium (e.g., an electronic display on a computer monitor or an electronic file which may be transferable), or in the form of a tangible medium (e.g., a report printed on paper or other tangible medium).
  • an electronic medium e.g., an electronic display on a computer monitor or an electronic file which may be transferable
  • a tangible medium e.g., a report printed on paper or other tangible medium.
  • the present disclosure contemplates the use of a computer system, computer readable medium, or software, with an input module for collecting input on levels of a plurality of biomarkers; a processor for performing an algorithm for performing a log 2 , log e or logio transformation of the biomarker levels, thus obtaining log transformed levels; a processor for performing an algorithm for normalizing each of the log transformed levels to normalized levels; a processor for performing an algorithm for adjusting each of the normalized levels to a weighted normalized level; a processor for an algorithm for totaling and optionally averaging each of the adjusted levels; a processor for an algorithm for providing a PE score based on the total amount, and a processor for optionally performing an algorithm for providing a PE index based on the preeclampsia score.
  • the computer preferably generates a report that can be provided to the caregiver and/or the subject female (e.g., pregnant female).
  • the report can include in it none, any or all of the following: name of patient or subject, gestation period at time of testing, list of markers analyzed, levels of each marker as measured in the sample, direct comparison of level of biomarkers to those in the training set, log transformed and normalized level of biomarkers as compared to log transformed and normalized levels in the training set, log transformed, normalized and weighted numbers of biomarkers, a PE score, a PE index, and recommended course of action for the subject.
  • the disclosure includes a system for diagnosing, prognosing, monitoring, characterizing, or evaluating the severity of preeclampsia, confirming the presence or the absence of PE in a female subject comprising: (a) an input module for receiving as input levels of one or more biomarkers, such as sFLT-1, P1GF and at least two other different biomarkers, (b) a processor optionally configured to perform algorithms such as (i) a log 2 , log e or logio transformation of the levels to obtain log transformed levels, (ii) normalizing each of the log transformed levels to normalized levels, (iii) adjusting each of said normalized levels to a weighted normalized level, (iv) totaling each of the adjusted levels, (v) averaging each of the adjusted levels; and (c) an output module for outputting a preeclampsia index based on a score wherein the index score comprises sFLT-l/PlGF and an addition of two other different biomarkers
  • the processor may perform an algorithm adjusting the levels of one or more biomarkers to a training set or a control value, thereby providing one or more adjusted biomarker levels.
  • the processor may further perform another algorithm that applies at least one binary operation using the adjusted biomarker levels, adds or subtracts the one or more adjusted biomarker level, calculates a ratio between two adjusted biomarker levels, and/or manipulates the one or more adjusted biomarker levels by multiplying one or more variables by one or more corresponding weight factors, wherein the level of each of the one or more adjusted biomarker levels is input into a specific variable, wherein the corresponding weight factor is unique for each specific variable, wherein at least one of the corresponding weight factors is not one.
  • the algorithm is a real function.
  • the disclosure includes a computer readable medium containing instructions which, when executed by a computer system, cause the computer system to receive a first data set pertaining to levels of PE biomarkers in a biological sample derived from a subject, and perform an analysis on those levels to obtain an assessment of PE in the subject.
  • the instructions when executed by a computer system, can cause the computer system to perform those steps a second time (e.g., receive a second data set pertaining to levels of PE biomarkers, and perform a second analysis to obtain a second assessment). In some cases, those steps may be performed at different points in time.
  • the instructions cause the computer system to compare the first assessment with the second assessment and confirm PE or the lack thereof based on the comparison.
  • the report may include information about the testing facility, which information is relevant to the hospital, clinic, or laboratory in which sample gathering and/or data generation was conducted.
  • Sample gathering can include deriving a fluid sample, e.g. blood, saliva, urine etc.; a tissue sample, e.g. a tissue biopsy, etc. from a subject.
  • Data generation can include measuring the level of polypeptide concentration for one or more genes that are differentially expressed or present at different levels in preeclampsia patients versus healthy individuals, e.g., individuals that do not have and/or do not develop preeclampsia.
  • This information can include one or more details relating to, for example, the name and location of the testing facility, the identity of the lab technician who conducted the assay and/or who entered the input data, the date and time the assay was conducted and/or analyzed, the location where the sample and/or result data is stored, or the lot number of the reagents (e.g., kit, etc.) used in the assay. Report fields with this information can be populated using information provided by the user.
  • the report may include information about the service provider, which may be located outside the healthcare facility at which the user is located, or within the healthcare facility. Examples of such information can include the name and location of the service provider, the name of the reviewer, and where necessary or desired the name of the individual who conducted sample gathering and/or data generation. Report fields with this information can be populated using data entered by the user, which can be selected from among pre-scripted selections (e.g., using a drop-down menu). Other service provider information in the report can include contact information for technical information about the result and/or about the interpretive report.
  • the report may include a patient data section.
  • the patient data section may include one or more items of the list consisting of patient medical history and symptoms (which can include, e.g., gestational period, blood pressure, proteinurea, diabetes, glucose level, body mass index, age, race, serotype, Papanicolaou test results (Pap smear), prior preeclampsia episodes, familial history, number of pregnancies, number of miscarriages, weight gain, water retention, hereditary factors, headache, edema, protein/creatinine ratio, current medications or past medications, stress, PE in prior pregnancies (of the subject or her family members), nulliparity, chronic hypertension, renal disease or thrombophilia, and any other
  • administrative patient data such as information to identify the patient (e.g., name, patient date of birth (DOB), gender, mailing and/or residence address, medical record number (MRN), room and/or bed number in a healthcare facility, insurance information, and the like), the name of the patient's physician or other health professional who ordered the monitoring assessment, and (if different from the ordering physician) the name of a staff physician who is responsible for the patient's care (e.g., primary care physician).
  • the report may include a sample data section, which may provide information about the biological sample analyzed in the monitoring assessment, such as the source of biological sample derived from the patient (e.g., blood, saliva, or type of tissue, etc.), how the sample was handled (e.g., storage temperature, preparatory protocols) or the date and time collected. Report fields with this information can generally be populated using data entered by the user, some of which may be provided as pre-scripted selections (e.g., using a drop-down menu).
  • the source of biological sample derived from the patient e.g., blood, saliva, or type of tissue, etc.
  • how the sample was handled e.g., storage temperature, preparatory protocols
  • Report fields with this information can generally be populated using data entered by the user, some of which may be provided as pre-scripted selections (e.g., using a drop-down menu).
  • the report may include an assessment report section, which may include information generated after processing of the data as described herein.
  • the interpretive report can include a prediction of the likelihood that the subject will develop PE, diagnosis of PE, a
  • the interpretive report can include, for example, the results of a protein level determination assay (e.g., "1.5 nmol/liter ADAM12 in serum”); and interpretation of that biomarker level, e.g., prediction, diagnosis, monitoring, characterization, evaluation of the severity of PE, or confirmation of the presence or absence of PE.
  • a protein level determination assay e.g., "1.5 nmol/liter ADAM12 in serum”
  • interpretation of that biomarker level e.g., prediction, diagnosis, monitoring, characterization, evaluation of the severity of PE, or confirmation of the presence or absence of PE.
  • the assessment portion of the report includes a recommendation(s).
  • the recommendation includes a recommendation that diet be altered, blood pressure medicines administered, bed-rest is recommended, pre-term labor recommended, diabetes medicines administered, etc., as recommended in the art.
  • the report may include at least one of diagnosis, prognosis, characteristics, monitor, severity of PE, or confirmation of the presence or absence of PE; a biomarker index value based on the analysis of one or more biomarkers detected in a biological sample from the pregnant subject.
  • the report may include the predictive performance of each biomarker panel analysis. In some instances, the predictive performance is evaluated by ROC curve analysis.
  • the reports can include additional elements or modified elements.
  • the report can contain hyperlinks which point to internal or external databases which provide more detailed information about selected elements of the report.
  • the patient data element of the report can include a hyperlink to an electronic patient record, or a site for accessing such a patient record, which patient record is maintained in a confidential database.
  • the inclusion of a hyperlink may be of interest in an in-hospital system or in-clinic setting.
  • the inclusion of a hyperlink may be of interest in a home or work setting.
  • the report is recorded on a suitable physical medium, such as a computer readable medium, e.g., in a computer memory, zip drive, floppy disc, USB chip, CD, DVD, or any other storage media capable of storing magnetic or electronic information that is retrievable.
  • a computer readable medium e.g., in a computer memory, zip drive, floppy disc, USB chip, CD, DVD, or any other storage media capable of storing magnetic or electronic information that is retrievable.
  • the report can include all or some of the elements above, with the proviso that the report generally includes at least the elements sufficient to provide the analysis requested by the user (e.g., prediction, diagnosis, monitoring, characterization, evaluation of the severity of preeclampsia, or confirmation of the absence or presence of preeclampsia).
  • the disclosure further provides a business method comprising the step of
  • the method comprises the steps of: evaluating levels of sFLT-1, P1GF and a plurality of biomarkers in a sample derived from the subject, wherein the plurality of biomarkers are not ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2-macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3), apolipoprotein A-l (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM), free human chorionic gonadotropin (free beta hCG) or heme, determining a
  • information about the subject including blood pressure, age, weight, gestational age, ethnicity, diabetes, kidney disease, autoimmune disease, maternal history, proteinurea, body mass index, swelling, abdominal pressure, uterine pulsatility index, thrombocytopenia, previous history of preeclampsia, previous history of eclampsia, first birth, multiple births, circulating free DNA, circulating fetal DNA, free DNA, fetal DNA, history of smoking or a family history of a related complicating factor.
  • the a plurality of biomarkers excludes endoglin, fibrinopeptide A, antithrombin III, IGFALS, FLT4, IGFBP-5, TGF-B1, fibrinopeptideA:D-dimer, ficolin-2, ficolin-3, creatinine, clusterin, H2 relaxin, P1GF-2,
  • the report is electronic.
  • the index is unaffected by at least one of blood pressure, age, weight, gestational age, ethnicity, diabetes, kidney disease, autoimmune disease, maternal history and a family history. In some cases, the index is unaffected by all of blood pressure, weight, ethnicity, diabetes, kidney disease, autoimmune disease, maternal history and a family history. In some cases, the index is unaffected by age. Sometimes, the index is unaffected by gestational age.
  • the disclosure further provides a business method comprising the step of determining the presence, absence, forecast, severity, or characteristics, of preeclampsia in a subject, or confirming the absence or presence of preeclamsia in a subject.
  • the method can comprise the steps of: (a) evaluating levels of sFLT-1, P1GF and at least two other different biomarkers in a sample derived from the subject, wherein the at least two other biomarkers are not ferritin (FT), cathepsin B (CTSB), cathepsin C (CTSC), haptoglobin (HP), alpha-2- macroglobulin (A2M), apolipoprotein E (ApoE), apolipoprotein C-III (Apo-C3),
  • apolipoprotein A-1 (ApoAl), retinol binding protein 4 (RBP4), hemoglobin (HB), fibrinogen alpha (FGA), pikachurin (EGFLAM), free human chorionic gonadotropin (free beta hCG) or heme
  • determining a biomarker index value the index comprising sFLT-l/PlGF and the addition of the at least two other different biomarkers
  • reagents, systems and kits thereof for practicing one or more of the above-described methods.
  • the subject reagents, systems and kits thereof may vary greatly. Variation may include alterations in incubation time and temperature.
  • Reagents of interest include reagents specifically designed for use in producing the above-described marker level representations of preeclampsia markers from a sample, for example, one or more detection elements.
  • the detection elements may be antibodies or peptides for the detection of protein, protein fragments.
  • the detection elements can be oligonucleotides for the detection of nucleic acids.
  • the detection element comprises a reagent to detect the expression of a single preeclampsia marker
  • the detection element may be a dipstick, a plate, an array, or cocktail that comprises one or more detection elements (e.g. one or more antibodies, one or more oligonucleotides, one or more sets of PCR primers, one or more sets of or isothermal polynucleotide amplification primers, etc.) which may be used to detect the expression of at least two preeclampsia markers simultaneously.
  • kits for detecting the presence, absence, forecast, severity or character of preeclampsia in subject includes a plurality of detection elements (analytes) used for measuring the plurality of biomarkers selected from the group consisting of PIGF, HPX, sFlt-1, PAPP-A, VEGF (excluding VEGF-R1), FN, FG, and ADAM 12.
  • PIGF PIGF
  • HPX PIGF
  • sFlt-1 sFlt-1
  • PAPP-A vascular endot-1
  • VEGF excluding VEGF-R1
  • FN FN
  • FG FG
  • ADAM 12 AdAM 12
  • at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 (or more) different reagents are utilized to measure at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 (or more) different biomarkers.
  • PIGF e.g., hPA18788.6 [152 aa], hPA18788.1 [1017 aa], hPA18788.2 [1009 aa], hPA18788.3 [775 aa], hPA18788.4 [403 aa], hPA18788.5 [375 aa] or hPA18788.9 [463 aa]).
  • PIGF as used herein is equivalent to PIGF or PLGF.
  • HPX hemopexin
  • one type of reagent specifically tailored for generating marker level representations is a collection of antibodies that bind specifically to the protein markers.
  • such antibodies may be employed in an ELISA (such as competitive or sandwich ELISA format).
  • ELISA competitive or sandwich ELISA format
  • Other analytic methodologies that may be employed include xMAPTM microsphere format, a proteomic array, suspension for analysis by flow cytometry, western blotting, dot blotting or immunohistochemistry. Methods for using the same are well understood in the art.
  • These antibodies can be provided in solution. Alternatively, they may be provided pre-bound to a solid matrix, for example, the wells of a multi-well dish or the surfaces of xMAP microspheres.
  • an array of probe nucleic acids in which the genes of interest are represented may be employed as reagents.
  • array formats are known in the art, with a wide variety of different probe structures, substrate compositions and attachment technologies (e.g., dot blot arrays, microarrays, etc.).
  • Representative array structures of interest include those described in U.S.
  • genes e.g. preeclampsia genes
  • a PCR-based technique e.g., realtime RT-PCR, or isothermal amplification techniques such as loop mediated isothermal amplification of DNA (LAMP), strand displacement amplification (SDA), sequence based amplification (NASBA), self-sustained sequence replication (3SR) and the like.
  • LAMP loop mediated isothermal amplification of DNA
  • SDA strand displacement amplification
  • NASBA sequence based amplification
  • 3SR self-sustained sequence replication
  • the kit may include polynucleotide primers that selectively hybridize polynucleotide sequences encoding selected biomarkers.
  • the primers selectively hybridize at least two polynucleotide sequences encoding proteins that are selected from the group consisting of P IGF, HPX, sFlt-1, PAPP-A, VEGF (excluding VEGF- Rl), FN, FG, and ADAM12.
  • Such primers may be DNA or RNA primers.
  • probes are also arrays of probes, collections of primers, or collections of antibodies that include probes, primers or antibodies (also called reagents) that are specific for at least one gene or protein selected from the group consisting PIGF, HPX, sFlt-1, PAPP- A, VEGF (excluding VEGF-R1), FN, FG, and ADAM 12.
  • reagents that are specific for at least one gene or protein selected from the group consisting PIGF, HPX, sFlt-1, PAPP- A, VEGF (excluding VEGF-R1), FN, FG, and ADAM 12.
  • VEGF excluding VEGF-R1
  • FN FN
  • FG FG
  • ADAM ADAM
  • the collection of probes, primers or antibodies include reagents specific for one or more of PIGF, HPX, sFlt-1, PAPP-A, VEGF (excluding VEGF-R1), FN, FG, and ADAM 12.
  • the subject probe, primer, or antibody collections or reagents may include reagents that are specific only for the genes, proteins or cofactors that are listed above, or they may include reagents specific for additional genes, proteins or cofactors that are not listed above, such as probes, primers, or antibodies specific for genes, proteins or cofactors whose expression pattern are known in the art to be associated with preeclampsia, e.g. sFLT-1 (VEGF-R1) and PIGF.
  • the systems and kits of the subject disclosure may include the above-described arrays, gene-specific primer collections, or protein-specific antibody collections.
  • the systems and kits may further include one or more additional reagents, such as bovine serum albumin (BSA), casein, solutions of powdered milk, bovine gamma globulin (BGG) in phosphate buffered saline (PBS)/Tween or
  • BSA bovine serum albumin
  • BGG bovine gamma globulin
  • PBS phosphate buffered saline
  • PBS/Triton-X 100 PBS/Tween, PBS/Triton-X 100, or borate buffer
  • selected solid surface preferably a surface exhibiting a protein affinity such as the wells of a polystyrene microtiter plate
  • second antibody will have an associated enzyme, e.g. urease, peroxidase, or alkaline phosphatase, and an appropriate chromogenic substrate.
  • urease e.g. urease, peroxidase, or alkaline phosphatase
  • peroxidase-conjugated anti-human IgG may be employed, PBS-containing solution such as PBS/Tween), a chromogenic substrate such as urea and bromocresol purple in the case of a urease label or 2,2'-azino-di-(3-ethyl-benzthiazoline)-6-sulfonic acid (ABTS) and H 2 0 2 , in the case of a peroxidase label. Quantitation is then achieved by measuring the degree of color generation, e.g., using a visible spectrum spectrophotometer.
  • the systems and kits may further include one or more additional reagents employed in the various methods, such as primers for generating target nucleic acids, dNTPs and/or rNTPs, which may be either premixed or separate, one or more uniquely labeled dNTPs and/or rNTPs, such as biotinylated or Cy3 or Cy5 tagged dNTPs, gold or silver particles with different scattering spectra, or other post synthesis labeling reagent, such as chemically active derivatives of fluorescent dyes, enzymes, such as reverse transcriptases, DNA polymerases, RNA polymerases, and the like, various buffer mediums, e.g.
  • hybridization and washing buffers prefabricated probe arrays, labeled probe purification reagents and components, like spin columns, etc.
  • signal generation and detection reagents e.g. labeled secondary antibodies, streptavidin-alkaline phosphatase conjugate, chemifluorescent or
  • the subject systems and kits may also include a preeclampsia phenotype
  • preeclampsia prognosis determination element which element is, in many cases, a reference or control sample or marker representation that can be employed, e.g., by a suitable experimental or computing means, to make a preeclampsia prognosis based on an "input" marker level profile, e.g., that has been determined with the above described marker determination element.
  • Representative preeclampsia phenotype determination elements include samples from an individual known to have or not have preeclampsia, databases of marker level representations, e.g., reference or control profiles, and the like, as described above.
  • the subject kits will further include instructions for practicing the subject methods. These instructions may be present in the subject kits in a variety of forms, one or more of which may be present in the kit.
  • One form in which these instructions may be present is as printed information on a suitable medium or substrate, e.g., a piece or pieces of paper on which the information is printed, in the packaging of the kit, in a package insert, etc.
  • a means would be a computer readable medium, e.g., diskette, floppy disc, USB device, CD, etc., on which the information has been recorded.
  • Some means may be present is a website address which may be used via the internet (i.e. via the cloud) to access the information at a removed site. Any convenient means may be present in the kits.
  • the present disclosure provides a business method for determining presence, absence, forecast, severity, monitor or character of PE in a subject.
  • Such method includes: performing an analysis of the subject's biological sample for the presence and amount of one or more biomarkers selected from a group consisting of P IGF, HPX, sFlt-1, PAPP-A, VEGF (excluding VEGF-R1), FN, FG, and ADAM 12; determining a weight, signature, score or index value of the biomarkers; employing the biomarker weight, signature, score or index value to provide a diagnosis, prognosis, severity, confirmation of presence, confirmation of absence, or characteristics of PE, and providing a report in exchange for a fee.
  • the present disclosure provides a business method for determining presence, determining absence, determining forecast, monitoring, determining severity, confirming presence of, confirming absence of or characterizing PE in a subject.
  • Such method includes: performing an analysis of the subject's biological sample for the presence and amount of one or more biomarkers selected from a group consisting of PIGF, HPX, sFlt- 1, PAPP-A, VEGF (excluding VEGF-R1), FN, FG, and ADAM 12.
  • the collection of probes, primers, or antibodies includes reagents specific for PIGF, HPX, sFlt-1, PAPP-A, VEGF (excluding VEGF-R1 ), FN, FG, and ADAM 12; determining a weight, signature, score or index value of the biomarkers; employing the biomarker weight, signature, score or index value to provide a diagnosis, prognosis, characteristic, confirmation presence , confirmation absence , or determination of the severity of PE and providing a report in exchange for a fee.
  • the index value is based on the analysis of biomarkers.
  • an indication of a range or threshold value is provided specifying whether the subject is at low risk of PE, high risk of PE, or experiencing PE.
  • the index value is based on the analysis of the biomarkers, and an indication of a range specifying whether the subject has mild PE, moderate PE, or severe PE.
  • an indication of the reliability or certainty of the confirmation is provided.
  • any method, kit, composition, business method, computer system disclosed herein may be used with a sample wherein the sample is a serum sample.
  • the sample is derived from blood, plasma, serum, urine, cells or body fluids.
  • the sample is derived from the mother or the fetus.
  • the sample is a vaginal swab.
  • the sample is not a urine sample.
  • the biomarker is a peptide.
  • the biomarker in a sample is a peptide, a portion of the peptide, a fragment of the peptide, a peptide containing an antigen, a portion of the peptide wherein the portion of the peptide contains an antigen, a fragment of the peptide wherein the fragment of the peptide contains an antigen.
  • evaluating comprises measuring a level of at least one R A molecule. In some cases, evaluating comprises performing at least one sequencing reaction. In some cases, the index is unaffected by blood pressure, age, weight, gestational age, ethnicity, diabetes, kidney disease, autoimmune disease, maternal history or a family history.
  • evaluating does not comprise comparing a sample derived from a subject at a first time point and a sample derived from the same subject at a second time point. In some cases, evaluating comprises comparing a sample derived from a subject at a first time point and a sample derived from the same subject at a second time point. In some cases, the evaluating step comprises determining the levels of a biomarker selected from the group consisting of sFlt-1, PIGF, VEGF (excluding VEGF-R1), ADAM 12, HPX, PAPP-A and FN.
  • the plurality of biomarkers excludes endoglin, fibrinopeptide A, antithrombin III, IGFALS, FLT4, IGFBP-5, TGF-B1, fibrinopeptideA:D-dimer, ficolin-2, ficolin-3, creatinine, clusterin, H2 relaxin, PIGF -2, P1GF-3 and human chorionic
  • the measuring is conducted using at least one antibody which recognizes a biomarker selected from the group consisting of sFlt-1, PIGF, VEGF (excluding VEGF-R1), ADAM 12, HPX, PAPP-A and FN.
  • the method does not include predicting preeclampsia in a subject that is asymptomatic of preeclampsia.
  • the evaluating does not comprise Doppler screening.
  • the method does not include detecting the presence of microvesicles or exosomes in the sample.
  • the method is greater than 85% accurate.
  • the method is greater than 85% sensitive.
  • the method is greater than 85%> specific.
  • the method is greater than 85% accurate. In some cases, the method has a positive predictive value greater than 85%. In some cases, the method has a negative predictive value greater than 85%.
  • the biomarker correlates with blood pressure, age, weight, gestational period, ethnicity, diabetes, kidney disease, autoimmune disease, maternal history, proteinurea, body mass index, swelling, abdominal pressure, uterine pulsatility index, thrombocytopenia, previous history of preeclampsia, previous history of eclampsia, the number of previous births given by the subject, circulating free DNA, circulating fetal DNA, free DNA, fetal DNA, history of smoking or a family history of a related complicating factor.
  • the biomarker does not correlate with blood pressure, age, weight, gestational age, ethnicity, diabetes, kidney disease, autoimmune disease, maternal history, proteinurea, body mass index, swelling, abdominal pressure, uterine pulsatility index, thrombocytopenia, previous history of preeclampsia, previous history of eclampsia, the number of previous births given by the subject, circulating free DNA, circulating fetal DNA, free DNA, fetal DNA, history of smoking or a family history of a related complicating factor.
  • the disclosure further provides a test for excluding diagnosis of preeclampsia, wherein said test measures one or more biomarkers from a sample derived from a subject and has an overall ROC value of at least 0.8, 0.85, 0.9, 0.95, 0.980, 0.981, 0.982, 0.983, 0.984, 0.985, 0.986, 0.987, 0.989, 0.990, 0.991, 0.992, 0.993, 0.994, 0.995, 0.996, 0.997, 0.998, 0.999 or more. In some cases, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 biomarkers are assayed.
  • the sample is a serum sample.
  • the sample is derived from blood, plasma, serum, urine, cells or body fluids.
  • the sample is derived from the mother or the fetus.
  • the sample is a vaginal swab.
  • the sample is not a urine sample.
  • the biomarker is a peptide.
  • the biomarker in a sample is a peptide, a portion of the peptide, a fragment of the peptide, a peptide containing an antigen, a portion of the peptide wherein the portion of the peptide contains an antigen, a fragment of the peptide wherein the fragment of the peptide contains an antigen.
  • the result of the test is unaffected by blood pressure, age, weight, gestational period, ethnicity, diabetes, kidney disease, autoimmune disease, maternal history or family history.
  • the test does not comprise comparing a sample derived from a subject at a first point in time and a sample derived from the same subject at a second point in time.
  • the test consists of comparing a sample derived from a subject at a first point in time and a sample derived from the same subject at a second point in time. In some cases, the test comprises determining the levels of a biomarker selected from the group consisting of sFlt-1, P1GF, VEGF (excluding VEGF-R1), ADAM 12, HPX, PAPP- A and FN.
  • a biomarker selected from the group consisting of sFlt-1, P1GF, VEGF (excluding VEGF-R1), ADAM 12, HPX, PAPP- A and FN.
  • the biomarkers excludes endoglin, fibrinopeptide A, antithrombin III, IGFALS, FLT4, IGFBP-5, TGF-B1, fibrinopeptideA:D-dimer, ficolin-2, ficolin-3, creatinine, clusterin, H2 relaxin, P1GF-2, P1GF-3 and human chorionic gonadotropin.
  • the test is conducted using at least one antibody which recognizes a biomarker selected from the group consisting of sFlt-1, PIGF, VEGF (excluding VEGF-Rl), ADAM 12, HPX, PAPP-A and FN.
  • the test does not include predicting preeclampsia in a subject that is asymptomatic. In some cases, the test does not consist of Doppler screening. In some cases, the test does not include detecting the presence of microvesicles or exosomes in the sample. In some cases, the test is at least 85, 90, 95% or more accurate. In some cases, the test is at least 85, 90, 95% or more sensitive. In some cases, the test is at least 85, 90, 95% or more specific. In some cases, the test has a positive predictive value of at least 85, 90, 95%. In some cases, the test has a negative predictive value of at least 85, 90, 95% or more .
  • the biomarker correlates with blood pressure, age, weight, gestational period, ethnicity, diabetes, kidney disease, autoimmune disease, maternal history, proteinurea, body mass index, swelling, abdominal pressure, uterine pulsatility index, thrombocytopenia, previous history of preeclampsia, previous history of eclampsia, the number of previous births given by the subject, circulating free DNA, circulating fetal DNA, free DNA, fetal DNA, history of smoking or a family history of a related complicating factor.
  • the biomarker does not correlate with blood pressure, age, weight, gestational age, ethnicity, diabetes, kidney disease, autoimmune disease, maternal history, proteinurea, body mass index, swelling, abdominal pressure, uterine pulsatility index, thrombocytopenia, previous history of preeclampsia, previous history of eclampsia, the number of previous births given by the subject, circulating free DNA, circulating fetal DNA, free DNA, fetal DNA, history of smoking or a family history of a related complicating factor.
  • the test includes performing a biological assay, a functional assay, an ELISA, an immunological assay, mass spectrometry, chromatography, mephelometry, radial immunodiffusion or single radial immunodiffusion.
  • the test includes digesting and measuring a biomarker.
  • the test includes derivatizing and measuring a biomarker.
  • the test includes isolating peptides from at least one cell in the sample.
  • the test further includes detecting polymorphisms or modifications to the biomarker.
  • the test further includes detecting RNA and/or DNA.
  • the test further includes detecting RNA and/or DNA associated with the biomarker.
  • the test further includes detecting transcription factors and/or transcription factor co-factors. In some cases, the test further includes detecting transcription factors and/or transcription factor co-factors associated with the biomarker. In some cases, the test further includes use of an algorithm, a threshold value, a directional change over time, comparing the index to a single patient, comparing the index to a control group or comparing the index to a reference standard. In some cases, the test is used to confirm the presence of preeclampsia in a subject wherein the subject has at least one symptom associated with preeclampsia. In some cases, the test is used to provide a diagnosis of preeclampsia in a subject wherein the subject has hypertension and proteinurea. In some instances, the test is used to provide a diagnosis of preeclampsia in a subject wherein the subject has hypertension.
  • the test is used to provide a diagnosis of preeclampsia in a subject wherein the subject has one risk factor associated with preeclampsia. In some cases, the test is used to determine if a subject is at risk for preeclampsia. In some cases, the test is used to quantify a risk that a subject will develop preeclampsia. In some cases, the test is used to predict a time at which a subject will develop preeclampsia. In some cases, the test is used to predict maternal and/or fetal outcomes of preeclampsia. In some cases, the test is used to distinguish between mild, moderate and severe preeclampsia.
  • the test is used to determine whether HELLP syndrome, preterm birth, interuterine growth restriction, placental abruption, placental accrete, low fetal birth weight, low size for gestational period, gestational hypertension, chronic hypertension, gestational diabetes, Type I diabetes, Type II diabetes or risk of spontaneous abortion are a result of the subject having preeclampsia.
  • the test further includes creating an electronic on non-electronic report.
  • the disclosure includes a test for excluding diagnosis of preeclampsia, wherein said test measures one or more biomarkers from a sample taken from a subject and has an overall ROC value of at least 0.8.
  • the test has a ROC value of at least 0.8, 0.85, 0.9, 0.95, 0.980, 0.981, 0.982, 0.983, 0.984, 0.985, 0.986, 0.987, 0.989, 0.990, 0.991, 0.992, 0.993, 0.994, 0.995, 0.996, 0.997, 0.998, 0.999 or more.
  • the disclosure further provides a kit for confirming the presence of PE, confirming the absence of PE, diagnosing, prognosing, monitoring, characterizing, or determining the severity of preeclampsia in a subject, said kit comprising at least two reagents that are specific for determining level of fibronectin in a sample from the subject.
  • the at least two reagents comprise two different antibodies that selectively bind fibronectin.
  • the kit further comprises reagents that are specific for determining levels of sFlt- 1 and P1GF in the sample.
  • the sample is a serum sample.
  • the sample is a blood sample.
  • the sample is not a urine sample.
  • the kit does not include a reagent to detect IGFALS, FLT4, P 1 GF, P 1 GF-2, P 1 GF-3 or sFlt- 1.
  • the disclosure further provides a kit for diagnosing, prognosing, monitoring, characterizing, determining the severity of preeclampsia, or confirming the presence or absence of preeclampsia in a subject, said kit comprising a first reagent specific for determining level of PAPP-A and a second reagent specific for determining ADAM 12.
  • the kit does not include a reagent to detect IGFALS, FLT4, P1GF, P1GF-2, PI GF-3 or sFlt-1.
  • the kit cannot be used to prognose, diagnose, screen for, determine or confirm Down's syndrome.
  • the kit cannot be used to prognose, diagnose, screen for, determine or confirm cardiovascular disease.
  • the biomarker is not PI GF-2 or PI GF-3.
  • the disclosure further provides a kit for confirming the presence of PE, confirming the absence of PE, diagnosing, prognosing, monitoring, characterizing or determining the severity of PE in a subject, said kit comprising at least two reagents that are specific for determining level of fibronectin in a sample from the pregnant woman.
  • the evaluating includes performing a biological assay, a functional assay, an ELISA, an immunological assay, mass spectrometry, chromatography,
  • the evaluating includes digesting and measuring a biomarker. In some cases, the evaluating includes derivatizing and measuring a biomarker. In some cases, the evaluating includes isolating peptides from at least one cell in the sample. In some cases, the method further includes detecting polymorphisms or modifications to the biomarker. In some cases, the method further includes detecting R A and/or DNA. In some cases, the method further includes detecting RNA and/or DNA associated with the biomarker. In some cases, the method further includes detecting transcription factors and/or transcription factor co-factors.
  • the method further includes detecting transcription factors and/or transcription factor co-factors associated with the biomarker. In some cases, the method further includes use of an algorithm, a threshold value, a threshold range, a directional change over time, comparing the index to a single patient, comparing the index to a control group or comparing the index to a reference standard. In some cases, the method is used to confirm a diagnosis of preeclampsia in a subject wherein the subject has at least one symptom associated with preeclampsia. In some cases, the method is used to provide a diagnosis of preeclampsia in a subject wherein the subject has hypertension and proteinurea.
  • the method is used to provide a diagnosis of preeclampsia in a subject wherein the subject has hypertension. In some cases, the method is used to provide a diagnosis of preeclampsia in a subject wherein the subject has one risk factor associated with preeclampsia. In some cases, the method is used to determine if a subject is at risk for preeclampsia. In some cases, the method is used to quantify a risk that a subject will develop preeclampsia. In some cases, the method is used to predict a time at which a subject will develop preeclampsia. In some cases, the method is used to predict maternal and/or fetal outcomes of preeclampsia.
  • the method is used to distinguish between mild, moderate and severe preeclampsia. In some cases, the method is used to determine whether HELLP syndrome, preterm birth, interuterine growth restriction, placental abruption, placental accrete, low fetal birth weight, low size for gestational age, gestational hypertension, chronic hypertension, gestational diabetes, Type I diabetes, Type II diabetes or risk of spontaneous abortion are a result from a subject having preeclampsia. In some cases, the method further includes creating an electronic report.
  • the disclosure further provides a kit for confirming the presence of PE, confirming the absence of PE, diagnosing, prognosing, monitoring , characterizing, or determining the severity of preeclampsia in a subject, said kit comprising a first reagent specific for determining level of PAPP-A and a second reagent specific for determining level of
  • the kit does not include a reagent to detect IGFALS, FLT4, PIGF, PIGF -2, P1GF-3 or sFlt-1. In some cases, the kit cannot be used to prognose, diagnose, screen for, determine or confirm Down's syndrome. In some cases, the kit cannot be used to prognose, diagnose, screen for, determine or confirm cardiovascular disease. In some cases, the biomarker is not PIGF -2 or P1GF-3.
  • the methods, compositions and reagents provided herein may be used for diagnosing, analyzing, distinguishing or confirming the presence or absence of preeclampsia (PE) in a female subject. Additionally, the methods, compositions and reagents provided herein may be used for diagnosing, analyzing, distinguishing or confirming preeclampsia (PE) in a female subject wherein the female subject also has other symptoms as described herein.
  • compositions and reagents find use in a number of applications, including, for example, predicting if an individual will develop preeclampsia, diagnosing preeclampsia, confirming the presence, absence or severity of preeclampsia, and monitoring an individual with preeclampsia.
  • the methods, compositions and reagents find use in a number of applications, including, for example, predicting if an individual will develop preeclampsia who has other symptoms as described herein, diagnosing preeclampsia in an individual who has other symptoms as described herein, confirming the presence, absence or severity of preeclampsia in an individual who has other symptoms as described herein, and monitoring an individual with preeclampsia in an individual who has other symptoms as described herein.
  • the other symptoms may include hypertension and proteinurea. In other cases, the other symptoms may include hypertension.
  • the methods, compositions and reagents may also find use in identifying an individual at risk for preeclampsia and quantifying the risk of preeclampsia in an individual. Often, the methods, compositions and reagents find use in predicting the time of the onset of preeclampsia. In some cases, the methods, compositions and reagents find use in predicting the timeline of progression of preeclampsia. The methods, compositions and reagents provided herein may find use to predict an outcome of preeclampsia, wherein the outcome affects the fetus or wherein the outcome affects the subject, often the mother.
  • the methods, compositions and reagents provided herein may find use to distinguish a stage of preeclampsia from another stage of preeclampsia.
  • a stage of preeclampsia may be mild or severe.
  • the methods, compositions and reagents provided herein may find use to distinguish preeclampsia from eclampsia.
  • the methods, compositions and reagents provided herein may find use to determine whether HELLP syndrome, risk of or ongoing process of preterm birth, risk of or ongoing interuterine growth restriction, risk of spontaneous abortion, risk of or ongoing placental abruption, risk of or ongoing placental accrete, risk of low or high fetal birth weight and risk of small or large size relative to gestational age are a result of the subject having preeclampsia.
  • compositions and reagents provided herein may further find use to distinguish patients having preeclampsia from patients not having preeclampsia but having symptoms associated with preeclampsia, such symptoms including complication of pregnancy symptoms, gestational hypertension, chronic hypertension, gestational diabetes, Type I diabetes and/or Type II diabetes.
  • the methods, compositions and reagents provided herein also find use in creating a report, often an electronic report, to communication the outcomes of the methods, compositions and reagents described herein.
  • the report may communicate preeclampsia score, preeclampsia index and/or preeclampsia profile of a subject.
  • This example demonstrates use of the disclosure described herein for performing an analysis of a set of samples derived from pregnant females, some of which did not have preeclampsia and some of which had preeclampsia using an ELISA method.
  • Use of the biomarkers demonstrated herein is a practical advancement for diagnosing, prognosing, monitoring, characterizing, predicting preeclampsia, or confirming the presence or absence of preeclampsia in a female subject.
  • the equipment used to perform ELISA assays included Eppendorf Research ® plus calibrated single and multi-channel pipettes, Accu-Jet ® pro pipettor, 2°-8°C deli refrigerator or cold room, -80°C freezer, non-humidified laboratory incubator set to 37°C, orbital microplate shaker, automated microplate washer (TitretekTM, M384 Washer with Stacker), microplate spectrophometer (Molecular Devices, SpectraMax ® 340PC), SoftMax® Pro software and an Alarm timer. Other equivalent equipment may be substituted for the above and achieve the same quality results.
  • Materials and reagents needed to perform the method include 0.5 mL and 2 mL deep well polypropylene dilution blocks, 15 mL and 50 mL polypropylene tubes, 5 mL, 10 mL and 25 mL disposable pipettes, and reagent troughs.
  • 10X PBST i.e.
  • Phosphate Buffered Saline with Tween® (1 L) was used for washing and was prepared by combining 80 g NaCl, 2 g KC1, 11.5 g Na 2 HP0 4 , 2 g KH 2 P0 4 , 5 ml Tween®-20 to 1 L in distilled water and 1 N sulfuric acid (0.1% Proclin 300 may be added to wash buffer as a preservative).
  • Calibrator and assay diluent includes either 1% BSA or animal serum in phosphate buffered saline. As known by those skilled in the art, diluents generally need to be optimized to maximize the detection of the marker of interest in complex matrices like serum and were optimized as such for the experiments described herein.
  • Serum samples derived from pregnant patient with or without preeclampsia and/or with a variety of comorbidities were obtained from typical sources including ProMedDx®, Discovery Life Sciences, Ortho Clinical Diagnostics, SeraCare®, etc. Samples were stored at -80°C, thawed at 4°C before use and snap frozen in LN2 after use. Stability of some markers tested was confirmed by accelerated freeze/thaw experiments. To reduce biological variability of clinical samples, templates of 20 to 32 serum samples (and quality control (QC) samples) were thawed at 4°C the night before an assay was run and tested in all assays on the same day. Templates
  • FIG. 3 and FIG. 4 Multiple different 96-well plate templates containing clinical samples, QC controls and standards can be used (see FIG. 3 and FIG. 4).
  • columns 1 and 2 contained duplicate, 8-point standard curves with 2-fold dilutions.
  • Column 12 contained an inverted 8- point standard curve or an inverted duplicate 4 point standard curve to address right to left and top to bottom variation.
  • 20 (triplicates) or 32 (duplicates) clinical serum samples were arrayed on the plate in a randomized fashion. For triplicates, samples were interleaved by column across the plate and for duplicates, samples were interleaved by row down the plate.
  • Each plate contained 4 or 6 replicates of Hi QC and Lo QC control samples arrayed strategically across the plate to assess top to bottom and left to right variation.
  • Serum samples were used undiluted or diluted between 1 :2 and 1 : 1,000 (typically 1 :4, 1 : 10, 1 : 15, 1 :20, or 1 : 1000) with assay diluent depending on the concentration range of the biomarker of interest in the samples (based on historical results). For example, for a 1 :2 dilution, 120 ⁇ of serum from the master block was added to 120 ⁇ of assay diluent in the dilution block. Standard solutions were diluted 1 : 10 if necessary for the first concentration and then a standard curve was made by making 1 :2 serial dilutions into calibrator diluent.
  • standard curves started at 50, 20, 10, 5, 2 or 1 nanograms per milliliter (ng/ml) for low concentration markers, but could start as high as 0.8, 2.5, or 5 microcrams per milliliter ⁇ g/ml) if the marker is at a high concentration if serum.
  • Hi and Lo QC controls were diluted similarly to serum samples or, sometimes, received a lower dilution due to the stock concentration of the QC controls.
  • QC controls were set up by spiking purified protein into normal or synthetic serum so that the OD of the QC control was at or near the second or fifth point on the standard curve.
  • ELISA protocol Assay plates pre-coated with capture antibody against the marker of interest were labeled with template number and marker as "T -Marker" for tracking. Assay plates were filled with 50 or 100 ⁇ of assay diluent prior to adding sample. Samples and standard curve samples were added to the plate as shown in the templates above. Plates were covered with an adhesive strip and incubated for 1, 2 or 3 hours at room temperature or 37°C (depending on the marker being tested). Plates were then washed on a plate washer with 3-6 washes of 300-400 ⁇ of wash buffer each then blotted on a paper towel.
  • Assay acceptance criteria The coefficient of determination of the standard curve can be R 2 > 0.95. Hi and Lo QC control values were tracked over time with a 3s control chart. QC control results may be used to alert the technical team that additional scrutiny may be appropriate. Any other variability in standard curve or QC controls (edge effects, left to right variation, etc.) are assessed by a statistician and reported in the study report.
  • Table 2 A listing of various PE biomarkers.
  • Homeobox protein Hox-B5 (HOXB5), thyrotropin-releasing hormone receptor (TRHR), nuclear transition protein 2 (TNP2), vasopressin, placental protein 13 (PP13), neutrophil gelatinase-associated lipocalin (LCN2), interferon gamma-inducible protein- 10 (IP- 10), monocyte chemotactic protein- 1 (MCP-1), intracellular adhesion molecule-1 (ICAM-1), intracellular adhesion molecule-3 (ICAM-3), vascular cell adhesion molecule- 1 (VCAM-1), interleukin-1 (IL-1), interleukin-2 (IL-2),
  • interleukin-3 interleukin-3
  • interleukin-4 interleukin-4
  • interleukin-5 IL-5
  • interleukin-6 IL-6
  • interleukin-7 IL-7
  • interleukin 8 interleukin-8
  • interleukin-9 IL-9
  • interleukin 10 IL-10
  • interleukin-11 IL-11
  • interleukin- 12 IL-12
  • interleukin 13 IL-13
  • interleukin-27 subunit beta EBI3
  • lectin platelet-derived growth factor
  • MMP-2 metalloprotease-2
  • MMP-9 matrix metalloprotease-9
  • MMP12 metalloprotease-12
  • MIFR matrix metalloprotease-23A
  • MIFR matrix metalloprotease-23A
  • MIFR-2 metalloprotease-23B
  • FGA fibrinogen alpha
  • FN1 fibronectin-1
  • PROS1 protein S
  • PROC protein C
  • EGFLAM pikachurin
  • HPX hemopexin
  • ADAM metallopeptidase domain 2 ADAM2
  • ADAM 12 ADAM metallopeptidase domain 12
  • ADAM12-S ADAM metallopeptidase domain 12 short isoform
  • ADAM 12- L ADAM metallopeptidase domain 12 long isoform
  • haptoglobin HP
  • serum-alpha2-macroglobulin A2M
  • retinol-binding protein 4 small inducible cytokine A2 (CCL2), C-C motif chemokine 5 (CCL5)
  • CTSB cathepsin B
  • CSC cathepsin C
  • CSD cathepsin D chain H
  • HMOXl heme oxygenase- 1
  • IGFBP1 insulin-like growth factor-binding protein 1
  • IGFBP2 insulin-like growth factor-binding protein 2
  • IGFBP3 insulin-like growth factor-binding protein-3
  • IGFBP5 insulin-like growth factor-binding protein-5
  • IGFBP7 insulin-like growth factor-binding protein-7
  • cytochrome P450-family 11 cytochrome P450-family 11
  • CYP11A1 cytochrome P450-family 11 subfamily A polypeptide 1
  • CYP11B1 cytochrome P450 1A1
  • CYP1A1 coronin- 2A
  • COR02A cytochrome P450 2J2
  • PLM paralemmin
  • GPD glyceraldehyde-3-phophase dehydrogenase
  • ABCA12 transcription factor Eb
  • TFIIE transcription factor HE
  • STXBP5L transcription factor Eb
  • TFIIE transcription factor HE
  • STXBP5L transcription factor Eb
  • GPIIE transcription factor HE
  • STXBP5L syntaxin binding protein 5-like (STXBP5L)
  • GPP1R16B protein phosphatase 1 regulatory subunit 16B
  • BHLHB2 class B basic helix-loop-helix protein 2
  • GYPE glyocophorin E
  • NEBL leucine-rich repeats and
  • LJG1 immunoglobulin- like domains protein 1
  • GLUT3 glucose transporter 3
  • UDP-glucuronosyltransferase 2B28 UDP-glucuronosyltransferase 2B28
  • NR5A2 nuclear receptor subfamily 5 group A member 2
  • NNAT neuronatin
  • SLC6A8 sodium- and chloride-dependent creatine transporter 1
  • ERBB2 receptor tyrosine-protein kinase erbB-2
  • ERBB3 receptor tyrosine-protein kinase erbB-3
  • SIGLEC6 SHC-transforming protein 3 (SHC3), neurexophilin 4 (NXPH4), lymphocyte antigen 6D (LY6D), prostacyclin synthase (PTGIS), ATP-dependent RNA helicase DDX51 (DDX51), TRAF3 -interacting protein 1 (TRAF3IP1), trophoblast glycoprotein (TPBG), transforming growth factor beta-3 (TGFB3), cyclin Bl (CCNB1), kinesin family member 17 (KIF17), N-myc downstream mediated gene 1 (NDRG1), SWI/SNF -related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 (SMARCD3), serine/threonine-protein kinase Chk2 (CHEK2), amphiregulin (AREG), minor histocompatibility antigen HA-1 (HA-1), POU domain, class 4, transcription factor 1 (POU4F1), prostate stem cell antigen (PSCA), collagen alpha-l(X) chain
  • COL6A3 collagen alpha-3 (IX) chain (COL9A3), paired box gene 2 (PAX2), paired box gene 4 (PAX4), paired box gene 7 (PAX7), latrophilin 3 (LPHN3), bile acid receptor (NR1H4), empty spiracles homolog 1 (EMX1), desmoglein 3 (DSG3), DNA- binding protein Ikaros (ZNFN1A1), melanoma-associated antigen 5 (MAGEA5), melanoma-associated antigen 3 (MAGEA3), afadin- and alpha-actinin-binding protein (SSX2IP), WD repeat-containing protein 21 (WDR21), orexin receptor type 2 (HCRTR2), NKG2-D type II integral membrane protein (KLRK1), HLA class II histocompatibility antigen DP alpha 1 chain (HLA-DPA1), HLA class II
  • HLA-DPB1 histocompatibility antigen DP beta 1 chain
  • HLA class II histocompatibility antigen DP beta 1 chain
  • HLA-DRA histocompatibility antigen DR alpha chain
  • HLA-G alpha chain G
  • PMP2 peripheral myelin protein 2
  • G(o) subunit alpha GNAOl
  • CACNB2 voltage- dependent L-type calcium channel subunit beta-2
  • MAPK8IP2 c-Jun-amino-terminal kinase-interacting protein 2
  • PAGE1 P antigen family member 1
  • GAB A receptor subunit beta-1 GAB A receptor subunit beta-1
  • SLC6A12 sodium- and chloride-dependent betaine transporter
  • MFGE8 lactadherin alpha-L
  • DSC1 desmocollin 1A/1B
  • VIL2 villin 2
  • PLC plectin 1
  • ANK1 ankyrin 1
  • VIM vimentin
  • SPP1 osteopontin
  • DDM2 dynamin 2
  • CDH15 muscle cadherin
  • kinesin heavy chain fatty acid synthase
  • FASN alpha-adducin
  • CYB5R NADH- cytochrome B5 reductase
  • DHFR dihydrofolate reductase
  • ADP- ribosylation factor- like protein 3 ADP- ribosylation factor- like protein 3 (ARL3)
  • NADPH menadione oxidoreductase 1- dioxin-inducible
  • UB ubiquitin
  • GSTM3 glutathione S-transferase Mu 3
  • SOD1 superoxide dismutase 1
  • COX6A1 cytochrome C oxida
  • FN Fibronectin
  • HPX Hemopexin
  • PAPP-A protein A
  • sFlt-1 growth factor
  • beta-amyloid
  • Isoforms of the above biological entities are also contemplated as biomarkers.
  • Such isoforms include, for example, sFlt-2, sFlt-4 and sFlt-5.
  • isoforms include FN GenBank Accession No. NM 212474.1), FG GenBank Accession
  • GenBank Accession No. NM 002581.3 HPX GenBank Accession No. NM 000613.2;
  • PE biomarkers Fragments or portions of a PE biomarker which are recognized by a detection reagent, e. an antibody, are also deemed PE biomarkers herein.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PCT/US2015/042976 2014-07-30 2015-07-30 Methods and compositions for diagnosing, prognosing, and confirming preeclampsia WO2016019176A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2956646A CA2956646A1 (en) 2014-07-30 2015-07-30 Methods and compositions for diagnosing, prognosing, and confirming preeclampsia
CN201580052632.5A CN107155350A (zh) 2014-07-30 2015-07-30 用于诊断、预后和确认先兆子痫的方法与组合物
EP15826348.3A EP3175239A1 (en) 2014-07-30 2015-07-30 Methods and compositions for diagnosing, prognosing, and confirming preeclampsia

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462031132P 2014-07-30 2014-07-30
US62/031,132 2014-07-30
US201462031834P 2014-07-31 2014-07-31
US62/031,834 2014-07-31
US201562115077P 2015-02-11 2015-02-11
US62/115,077 2015-02-11

Publications (1)

Publication Number Publication Date
WO2016019176A1 true WO2016019176A1 (en) 2016-02-04

Family

ID=55218328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/042976 WO2016019176A1 (en) 2014-07-30 2015-07-30 Methods and compositions for diagnosing, prognosing, and confirming preeclampsia

Country Status (5)

Country Link
EP (1) EP3175239A1 (zh)
CN (1) CN107155350A (zh)
CA (1) CA2956646A1 (zh)
MA (1) MA40325A (zh)
WO (1) WO2016019176A1 (zh)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017148854A1 (en) * 2016-02-29 2017-09-08 Roche Diagnostics Gmbh Igfbp-7 as a marker in preeclampsia
CN107312846A (zh) * 2017-07-12 2017-11-03 北京赛尔维康生物医学科技有限公司 Capg和ptgis基因在制备脊柱侧弯检测试剂盒中的应用
FR3057070A1 (fr) * 2016-10-04 2018-04-06 Inst Nat Sante Rech Med Diagnostique et pronostique precoce de la preeclampsie
WO2020091173A1 (ko) * 2018-10-31 2020-05-07 서울대학교산학협력단 임신성 당뇨 및 임신 중 고혈압 예측을 위한 바이오마커
CN111257445A (zh) * 2020-01-22 2020-06-09 上海交通大学医学院附属仁济医院 用于sle孕妇病情监测及其胎儿结局预测的产品及方法
KR20200098440A (ko) * 2020-07-13 2020-08-20 서울대학교산학협력단 임신성 당뇨 및 임신 중 고혈압 예측을 위한 바이오마커
CN112535886A (zh) * 2020-11-12 2021-03-23 杭州苏铂科技有限公司 去除金纳米棒溶液中的ctab的方法
US20210140971A1 (en) * 2018-07-20 2021-05-13 Roche Diagnostics Operations, Inc. Prediction of preeclampsia based on igfbp-7
US11112403B2 (en) 2019-12-04 2021-09-07 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
WO2022038064A1 (en) * 2020-08-17 2022-02-24 University Of Tartu Method of prognosing preeclampsia
US11333672B2 (en) 2017-09-13 2022-05-17 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
WO2023087004A3 (en) * 2021-11-11 2023-06-22 Nx Prenatal Inc. Methods of preparing and analyzing samples for biomarkers associated with placenta accreta
RU2804645C1 (ru) * 2023-05-24 2023-10-03 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Способ диагностики степени тяжести преэклампсии на фоне хронической артериальной гипертензии у беременных женщин

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3701043B1 (en) * 2017-10-23 2023-11-22 CZ Biohub SF, LLC A noninvasive molecular clock for fetal development predicts gestational age and preterm delivery
AU2019218548A1 (en) * 2018-02-09 2020-09-03 Metabolomic Diagnostics Limited Methods of predicting pre term birth from preeclampsia using metabolic and protein biomarkers
CN108717123A (zh) * 2018-04-25 2018-10-30 卢英 一种联合检测sFlt-1/PLGF和HLA-G检测先兆子痫的方法
CN109554479A (zh) * 2019-01-21 2019-04-02 中南大学 Pigc基因在制备肝癌辅助诊断及预后判断制剂上的应用
CN109919054B (zh) * 2019-02-25 2023-04-07 电子科技大学 一种基于机器视觉的试剂卡自动分类的检测方法
CN110596386B (zh) * 2019-09-20 2020-06-02 四川大学华西医院 Egflam自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN112710836A (zh) * 2019-10-25 2021-04-27 成都敬守务成医疗科技有限责任公司 人类白细胞抗原g标志物的用途及试剂盒
CN112180098B (zh) * 2019-12-06 2023-02-17 中山大学 胎盘相关疾病标志物的筛选方法及标志物
CN112305220B (zh) * 2020-06-03 2021-07-23 四川大学华西第二医院 组织蛋白酶z在子痫前期的早期预警、诊断中的应用和产品
CN111951969A (zh) * 2020-08-05 2020-11-17 中翰盛泰生物技术股份有限公司 Hbp在高危妊娠预测中的应用
CN112175963A (zh) * 2020-09-30 2021-01-05 安徽省天长市周氏羊业有限公司 一种spp1基因及评估绵羊单卵泡中高尔基体发育质量的方法
CN112946299B (zh) * 2021-01-29 2022-11-29 暨南大学 定量ftl的产品在制备子痫前期诊断工具中的应用
CN112946283B (zh) * 2021-01-29 2022-11-29 暨南大学 定量a2m的产品在制备子痫前期诊断工具中的应用
CN113092777B (zh) * 2021-03-26 2023-11-14 泰达国际心血管病医院 孕早期进行重症子痫前期患者筛查的方法
CN117867094A (zh) * 2022-10-10 2024-04-12 天津云检医疗器械有限公司 用于先兆子痫风险预测、评估或诊断的生物标志物、试剂盒及方法
CN117647653B (zh) * 2023-12-22 2024-05-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 一种与子痫前期相关的生物标志物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069373A2 (en) * 2004-12-21 2006-06-29 Yale University Diagnosis of preeclampsia
WO2009097584A1 (en) * 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2013169751A1 (en) * 2012-05-08 2013-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for providing a preeclampsia assessment
WO2014036440A2 (en) * 2012-08-30 2014-03-06 Ansh Labs Llc Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069373A2 (en) * 2004-12-21 2006-06-29 Yale University Diagnosis of preeclampsia
WO2009097584A1 (en) * 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2013169751A1 (en) * 2012-05-08 2013-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for providing a preeclampsia assessment
WO2014036440A2 (en) * 2012-08-30 2014-03-06 Ansh Labs Llc Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
LIU, L. Y. ET AL.: "Integrating multiple 'omics' analyses identifies serological protein biomarkers for preeclampsia", BMC MEDICINE, vol. 11, 2013, pages 236, XP021166655, DOI: doi:10.1186/1741-7015-11-236 *
MOLVAREC, A. ET AL.: "Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia", HYPERTENSION RESEARCH, vol. 33, 2010, pages 892 - 898, XP055268313 *
MYATT, L.: "Association of maternal biomarkers with obstetric outcomes", REPRODUCTIVE SCIENCES, vol. 20, no. Suppl. 1, 20 March 2013 (2013-03-20), Orlando, FL, USA, XP008185257 *
MYATT, L.: "Identification of different phenotypes of preeclampsia by clustering analysis of biomarker profiles", REPRODUCTIVE SCIENCES, vol. 20, no. Suppl. 1, 20 March 2013 (2013-03-20), Orlando, FL, USA, XP008185256 *
PARK, H. J. ET AL.: "Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy", BMC PREGNANCY AND CHILDBIRTH, vol. 14, 2014, pages 35, XP021178101, DOI: doi:10.1186/1471-2393-14-35 *
PENNINGS, J. L. A. ET AL.: "Integrative data mining to identity novel candidate serum biomarkers for pre-eclampsia screening", PRENATAL DIAGNOSIS, vol. 31, 2011, pages 1153 - 1159, XP055390049 *
SPENCER, K. ET AL.: "ADAM12s in maternal serum as a potential marker of pre- eclampsia", PRENATAL DIAGNOSIS, vol. 28, 2008, pages 212 - 216, XP055390059 *
TEJERA, E. ET AL.: "Preeclampsia: a bioinformatics approach through protein-protein interaction networks analysis", BMC SYSTEMS BIOLOGY, vol. 6 : 97, 2012, XP021107964 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108700599A (zh) * 2016-02-29 2018-10-23 豪夫迈·罗氏有限公司 Igfbp-7作为先兆子痫中的标志物
US20180364248A1 (en) * 2016-02-29 2018-12-20 Roche Diagnostics Operations, Inc. Igfbp-7 as a marker of preeclampsia
US11874282B2 (en) 2016-02-29 2024-01-16 Roche Diagnostics Operations, Inc. IGFBP-7 as a marker of preeclampsia
WO2017148854A1 (en) * 2016-02-29 2017-09-08 Roche Diagnostics Gmbh Igfbp-7 as a marker in preeclampsia
FR3057070A1 (fr) * 2016-10-04 2018-04-06 Inst Nat Sante Rech Med Diagnostique et pronostique precoce de la preeclampsie
WO2018065730A1 (fr) * 2016-10-04 2018-04-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Diagnostique et pronostique précoce de la prééclampsie
CN107312846A (zh) * 2017-07-12 2017-11-03 北京赛尔维康生物医学科技有限公司 Capg和ptgis基因在制备脊柱侧弯检测试剂盒中的应用
US11333672B2 (en) 2017-09-13 2022-05-17 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
JP2021532378A (ja) * 2018-07-20 2021-11-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Ｉｇｆｂｐ−７に基づく妊娠高血圧腎症の予測
JP7557463B2 (ja) 2018-07-20 2024-09-27 エフ． ホフマン－ラ ロシュ アーゲー Ｉｇｆｂｐ－７に基づく妊娠高血圧腎症の予測
US20210140971A1 (en) * 2018-07-20 2021-05-13 Roche Diagnostics Operations, Inc. Prediction of preeclampsia based on igfbp-7
WO2020091173A1 (ko) * 2018-10-31 2020-05-07 서울대학교산학협력단 임신성 당뇨 및 임신 중 고혈압 예측을 위한 바이오마커
US11327071B2 (en) 2019-12-04 2022-05-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
US11112403B2 (en) 2019-12-04 2021-09-07 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
CN111257445B (zh) * 2020-01-22 2022-09-09 上海交通大学医学院附属仁济医院 用于sle孕妇病情监测及其胎儿结局预测的产品及方法
CN111257445A (zh) * 2020-01-22 2020-06-09 上海交通大学医学院附属仁济医院 用于sle孕妇病情监测及其胎儿结局预测的产品及方法
KR102233909B1 (ko) * 2020-07-13 2021-03-30 서울대학교산학협력단 임신성 당뇨 및 임신 중 고혈압 예측을 위한 바이오마커
KR20200098440A (ko) * 2020-07-13 2020-08-20 서울대학교산학협력단 임신성 당뇨 및 임신 중 고혈압 예측을 위한 바이오마커
WO2022038064A1 (en) * 2020-08-17 2022-02-24 University Of Tartu Method of prognosing preeclampsia
CN112535886A (zh) * 2020-11-12 2021-03-23 杭州苏铂科技有限公司 去除金纳米棒溶液中的ctab的方法
CN112535886B (zh) * 2020-11-12 2022-07-12 杭州苏铂科技有限公司 去除金纳米棒溶液中的ctab的方法
WO2023087004A3 (en) * 2021-11-11 2023-06-22 Nx Prenatal Inc. Methods of preparing and analyzing samples for biomarkers associated with placenta accreta
RU2804645C1 (ru) * 2023-05-24 2023-10-03 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Способ диагностики степени тяжести преэклампсии на фоне хронической артериальной гипертензии у беременных женщин

Also Published As

Publication number Publication date
MA40325A (fr) 2016-02-04
CN107155350A (zh) 2017-09-12
EP3175239A1 (en) 2017-06-07
CA2956646A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
WO2016019176A1 (en) Methods and compositions for diagnosing, prognosing, and confirming preeclampsia
US10961584B2 (en) Biomarker pairs for predicting preterm birth
US20150099655A1 (en) Methods and Compositions for Providing a Preeclampsia Assessment
JP2023110034A (ja) 臨床的介入のための妊娠の進展および早期流産の評価方法およびその応用
US20180172698A1 (en) Biomarkers for predicting preterm birth due to preterm premature rupture of membranes (pprom) versus idiopathic spontaneous labor (ptl)
JP6691617B2 (ja) 子癇前症の評価を提供するための方法及び組成物
US20100029006A1 (en) Multiplexed diagnostic test for preterm labor
CN109891239B (zh) 用于提供子痫前期评估和预测早产的方法和试剂盒
US9983215B2 (en) Methods and compositions for diagnosis of ectopic pregnancy
WO2017181367A1 (en) Methods and compositions for prognosing preterm birth
EP2153233A1 (en) Method for predicting the outcome of a critically ill patient
EP3982123A1 (en) Markers and their use in brain injury
KR102317330B1 (ko) 프로칼시토닌 측정을 통한 개 자궁 축농증의 예후 판정용 조성물
WO2022186821A1 (en) Methods and compositions for providing a preeclampsia assessment using leptin and ceramide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15826348

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2956646

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015826348

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015826348

Country of ref document: EP